

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## A cross-sectional study of clinical, neurocognitive, and demographic factors associated with functional impairment in the Brain and Mind Youth Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022659
Article Type:	Research
Date Submitted by the Author:	01-Mar-2018
Complete List of Authors:	Lee, Rico; Monash University School of Psychological Sciences Hermens, Daniel; Brain & Mind Research Institute , Naismith, Sharon; Brain & Mind Research Institute, Kaur, Manreena; Monash Alfred Psychiatry Research Centre Guastella, Adam; Brain & Mind Research Institute, Clinical Research Unit Glozier, Nick; Brain & Mind Research Institute, Clinical Research Unit Scott, Jan; Newcastle University, Institute of Neuroscience Scott, Elizabeth; Brain & Mind Research Institute, Hickie, Ian; The University of Sydney, Brain and Mind Centre;
Keywords:	neurocognition, transdiagnostic, functional impairment, mental illness, symptom dimensions, alcohol use

SCHOLARONE™  
Manuscripts

1  
2  
3 **A CROSS-SECTIONAL STUDY OF CLINICAL, NEUROCOGNITIVE,**  
4 **AND DEMOGRAPHIC FACTORS ASSOCIATED WITH FUNCTIONAL**  
5 **IMPAIRMENT IN THE BRAIN AND MIND YOUTH COHORT**  
6  
7  
8  
9  
10  
11  
12

13 Rico S C Lee<sup>1,2</sup>, Daniel F Hermens<sup>ψ1,3</sup>, Sharon L Naismith<sup>1,4</sup>, Manreena Kaur<sup>1,5</sup>, Adam J  
14 Guastella<sup>1</sup>, Nick Glozier<sup>1,6</sup>, Jan Scott<sup>7,8</sup>, Elizabeth M Scott<sup>1</sup>, Ian B Hickie<sup>1</sup>  
15  
16  
17  
18  
19  
20

21 <sup>1</sup> Brain and Mind Centre, University of Sydney, Australia  
22

23 <sup>2</sup> Brain and Mental Health Laboratory, Monash University, Australia  
24

25 <sup>3</sup> Sunshine Coast Mind and Neuroscience Thompson Institute, University of the Sunshine  
26 Coast, QLD, Australia  
27

28 <sup>4</sup> Charles Perkins Centre, University of Sydney, Australia  
29

30 <sup>5</sup> The Monash Alfred Psychiatry Research Centre, Monash University, Australia  
31

32 <sup>6</sup> Marie Bashir Institute, University of Sydney, Australia  
33

34 <sup>7</sup> Academic Psychiatry, Institute of Neuroscience, Newcastle University, UK  
35

36 <sup>8</sup> Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, UK  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

47 Abstract word count: 243  
48

49 Manuscript word count: 3588  
50

51 Tables and figures: 3 tables, 2 figures  
52

53 <sup>ψ</sup> Corresponding author: Dr Rico S. C. Lee, Monash Biomedical Imaging, 770 Blackburn  
54 Rd, Clayton VIC, 3800; Phone: +61 3 9902 9808; Email: rico.lee@monash.edu.  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Objectives:** To determine the unique and shared contributions of clinical, neurocognitive, and demographic factors to functional impairment in a large, transdiagnostic, clinical cohort of adolescents and young adults.

**Design:** Cross-sectional baseline data from a prospective, cohort study.

**Setting:** Help-seeking youth referred from outpatient services were recruited to the *Brain and Mind Youth Cohort* (2008-2016) in Sydney, Australia.

**Participants:** In total, 1003 outpatients were recruited, aged between 12 and 36 years (M = 20.4 years, 54% female), with baseline diagnoses of affective, psychotic, developmental or behavioural disorders.

**Interventions:** Treatment as usual by referring clinicians.

**Primary outcome measures:** Social and occupational functioning was used to index level of functional impairment. Structural equation modelling was employed to examine associations between neurocognition, core clinical symptoms, alcohol and substance use, sleep and circadian changes, and clinician- and researcher-rated functional impairment. Moderator analyses were conducted to determine the potential influence of demographic and clinical factors (e.g. medication exposure).

**Results:** Independent of diagnosis, we found that neurocognitive impairments, and depressive, anxiety and/or negative symptoms, were significantly associated with functioning. The association of neurocognition with social and occupational functioning remained significant even when age (younger) and diagnosis (affective disorder) were included in the model.

**Conclusions:** This study demonstrated that, in a clinically representative sample of youth, the key determinants of functioning may not be disorder specific. Further, evidence of

1  
2  
3 neurocognitive dysfunction suggests that interventions that target cognition and  
4  
5 functioning should not necessarily be reserved only for older adults with established  
6  
7 illness.  
8  
9

10  
11  
12 **Keywords:** Neurocognition; transdiagnostic; functional impairment; mental illness; symptom  
13  
14 dimensions; alcohol use.  
15

### 16 17 18 **STRENGTHS AND LIMITATIONS OF THIS STUDY** 19

- 20  
21 • This was one of the largest studies to date (N > 1,000) to examine the associations  
22  
23 between a broad range of illness characteristics and functional impairment in an  
24  
25 adolescent and young adult clinical sample.  
26
- 27 • Given the transdiagnostic approach, this study was equipped to disentangle the shared  
28  
29 and unique associations between core illness phenotypes and functional impairment  
30  
31 across a range of common mental disorders.  
32
- 33 • The use of latent-variable, structural equation modelling controlled for aspects of  
34  
35 measurement imprecision.  
36
- 37 • The main limitation of this study was that it was cross-sectional and, as such, the  
38  
39 direction of effects remains unclear.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

In recent decades, early intervention services for youth with emerging mental disorders have extended their targets beyond those at risk of psychosis to also encompass those presenting with mood and other developmental and anxiety disorders. This approach creates several significant challenges. For example, some youth with depressive and anxiety disorders will ultimately develop psychotic or bipolar disorders; likewise, only a proportion of those receiving a diagnosis of bipolar disorders will consistently receive this diagnosis over the following 10 years.<sup>1</sup> The lack of diagnostic stability in help-seeking youth reflects the evolving disease process and means that the illness trajectory is less certain than for older adults with established illness.<sup>2 3</sup> From a research perspective, the use of dimensional approaches to phenomenology has helped us to understand illness progression in these early clinical stages, whilst from a clinical perspective, care and treatment have increasingly considered transdiagnostic interventions addressing core factors that may influence prognosis irrespective of cross-sectional diagnosis (e.g., anxiety, depressive or negative symptoms; sleep disturbances).<sup>4 5</sup> These approaches have highlighted that, in youth, a more meaningful measure of outcome may be functioning rather than change in diagnosis-specific symptoms. There is evidence to support this approach as level of functioning or disengagement (e.g., not being in education, employment or training, referred to as being NEET) is associated with early transition to major mental disorder<sup>6</sup> and with poor outcome of acute illness episodes.<sup>7 8</sup> However, to optimize interventions that target functioning it is important to understand the demographic and clinical factors that contribute to level of functioning at clinical presentation. For instance, as well as transdiagnostic symptom dimensions, it is likely that other factors such as neurocognitive functioning and alcohol or substance use will also affect overall functioning. Disentangling the contribution and magnitude of any effects of these

1  
2  
3 factors on functioning is important to determine which factors may be amenable to  
4 modification and allow clinicians to design a multidimensional intervention package.  
5  
6

7  
8 The proposal that social and occupational functioning should be a primary target for  
9 mental health interventions is not new and is increasingly promoted for older adults with  
10 established illness. For example, senior policy experts in the U.S. have stipulated that  
11 recovery-oriented treatments should form the overarching goal of mental health care and the  
12 foundation of strategic health policy.<sup>9</sup> The recognition that more personalized interventions  
13 are urgently needed to enhance functioning and quality of life rather than simply targeting  
14 diagnosis-specific symptoms is also emphasized by the World Health Organization.<sup>10</sup> Given  
15 this interest in enhancement of functioning across all stages of mental illness and for youth  
16 and adults presenting to mental health services, it is useful to examine the role of  
17 demographic and clinical factors in determining functioning.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29  
30 Most path modelling studies to date have used small, and single- or dual-diagnosis  
31 cohorts, predominantly in individuals with a chronic mental illness. Findings consistently  
32 demonstrate that neurocognition and negative symptoms are robust predictors of functional  
33 outcome in schizophrenia and bipolar disorder.<sup>7 11 12</sup> By contrast, the impact of affective and  
34 positive symptoms on functioning remains more equivocal. Overall, these findings have been  
35 replicated in large schizophrenia cohort studies more recently,<sup>13 14</sup> although the vast majority  
36 of existing studies have focused solely on schizophrenia. There have been no well-powered  
37 studies examining a mental disorder other than schizophrenia, such as affective disorders,  
38 despite depression being the leading cause of disability worldwide.<sup>15</sup> Studies have also largely  
39 sidestepped the issue of psychotropic medication use. Furthermore, given that more than 75%  
40 of mental illnesses emerge before the age of 25,<sup>3</sup> examining younger cohorts is critically  
41 important for the development of novel approaches to early intervention since most studies to  
42 date have targeted older individuals.<sup>15</sup>  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In order to build upon prior research, a transdiagnostic and dimensional approach is  
4 ideally positioned to disentangle the factors that are associated with functioning. Key to this  
5 research strategy is the examination of shared constructs (e.g., neurocognition) with clear  
6 links to pathophysiology,<sup>16-18</sup> which can inform novel therapeutics that target specific neural  
7 circuitries.<sup>17 19</sup> Transdiagnostic studies are also able to harness the variance across disorders,  
8 with the goal of developing robust, unifying models that are *explanatory* in nature.<sup>2</sup> Data  
9 showing that physiological and genetic risk factors for mental illness extend across, rather  
10 than are bound by, traditional diagnoses,<sup>20</sup> further supports this paradigm, as does the frequent  
11 prescription of psychotropic medications for off-label use across diagnostic boundaries.<sup>21</sup>  
12 Transdiagnostic studies are also superior to single-diagnosis case-control studies in that they  
13 can determine which relationships are *shared* across various diagnoses and which are *unique*  
14 to a particular disorder.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

29 In this study, we sought to determine whether: (i) neurocognition; (ii) core clinical  
30 dimensions; and (iii) alcohol and substance use, are associated with social and occupational  
31 functioning and the magnitude of these associations. In keeping with prior research,<sup>7 12 22</sup> it  
32 was hypothesized that neurocognition and negative symptoms would make the greatest  
33 contribution to level of social and occupational functioning irrespective of the cross-sectional  
34 diagnosis applied to cases at the time of inclusion in the cohort.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

## 45 **METHODS**

46  
47 This study was approved by the University of Sydney Human Research Ethics Committee.  
48 Data included in the current study represent the baseline assessments conducted at entry to the  
49 cohort study, and were collected between April 2008 and May 2016.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Participants

Participants were recruited into the Brain and Mind Youth Cohort from youth mental health outpatient services at the Brain and Mind Centre.<sup>23 24</sup> Referred participants were 12–36 years of age and presented with a major affective, psychotic or developmental/behavioral syndrome. Participants were excluded if they (or their guardians, if aged under 16 years) were unwilling or unable to provide written informed consent, or if they had a pre-existing neurological condition, clinically assessed impaired English language skills and/or intellectual disability that precluded completion of study self-ratings. Eligible participants completed a series of observer and self-rated questionnaires.

## Procedure

Treating clinicians recorded clinical diagnoses and these were reviewed at consensus meetings by senior, treating psychiatrists (e.g., IBH, EMS) and formal diagnoses recorded based on the DSM-IV-TR (Table 1 provides details of diagnoses and sample characteristics). All participants received their prescribed course of medications and interventions, as independently determined in consultation with their treating clinicians.

Treating clinicians (i.e., psychiatrists, clinical psychologists, mental health nurses) provided an evaluation of each participant's social and occupational functioning. Next, clinical psychologists, clinical neuropsychologists, or trained research psychologists (supervised by RSCL to ensure a sufficient level of inter-rater reliability), conducted structured clinical interviews, neuropsychological testing, as well as an additional assessment of social and occupational functioning to improve the reliability of this single, clinician-rated score (approximately 80% were conducted within a month of the treating clinician assessment).

## Measures

- *Social and occupational functioning* was indexed using the Social and Occupational Assessment Functioning Scale (SOFAS<sup>25</sup>). Scores were averaged across the treating clinician and researcher assessments (ICC = 0.70), as previously done.<sup>26</sup> This composite score was derived to obtain a more reliable estimate of real-world functioning and, secondarily, to conserve free parameters and increase stability of parameter estimates.<sup>22 27</sup>
- *Neurocognition* was assessed using a broad neuropsychological battery with demographic normative-adjustments (previously described<sup>22</sup>), and was chosen on the basis of sound psychometric properties<sup>28</sup> and relevance to the disorders under study.<sup>29</sup> Predicted IQ was estimated using the Wechsler Test of Adult Reading (WTAR) or Wide Range Achievement Test—fourth edition (WRAT-4, for participants younger than 16 years). Psychomotor speed and mental flexibility were measured using Trail Making Test—Part A (TMT-A) and -Part B (TMT-B). Verbal learning and memory were indexed using the five-trial total and delayed recall scores from the Rey Auditory Verbal Learning Test (RAVLT). Verbal fluency was comprised of the letter (FAS) and category (animals) fluency subtests of the Controlled Oral Word Association Test.
- *Core clinical symptom dimensions* were measured across two validated scales. Symptoms were rated on the expanded Brief Psychiatric Rating Scale (BPRS) using empirically-derived symptom sub-scores (depression and anxiety, mania, positive symptoms, negative symptoms, and disorientation<sup>30</sup>). The BPRS does not capture sleep profiles as a separate dimension so, as in previous studies,<sup>31</sup> disturbed sleep was indexed using the sum of the three sleep items from the Hamilton Depression Rating Scale (HDRS<sup>32</sup>).

- *Alcohol and substance use* were measured across two validated scales. Alcohol use was indexed using the Alcohol Use Disorders Identification Test (AUDIT<sup>33</sup>) total score. Substance use for tobacco, cannabis, and other illicit substances was measured using the ‘current frequency’ sub-scale (past 3 months) from the World Health Organization – Alcohol, Smoking and Substance Involvement Screening Test (WHO-ASSIST) questionnaire.<sup>34</sup>

### Data Analysis

Statistical analyses were conducted using IBM SPSS 20.0 and AMOS 20.0. Maximum likelihood estimation (MLE) was employed for all structural equation modelling (SEM) analyses. MLE was chosen as it is the most robust approach in the potential event of statistical assumption violations and performs best in heterogeneous samples<sup>35</sup>. Missing data was also handled by MLE, which does not involve data imputation, but uses all available data to compute maximum likelihood estimates. Diagnostic and demographic data were available for all participants. Each analysis (univariate and multivariate) had at least 80% of cases with complete data.

We first used SEM to evaluate the best-fitting *measurement model* for the following predictors: 1/ neurocognition; 2/ clinical symptoms and disturbed sleep; and 3/ alcohol and substance use. Then, we used SEM to test the *structural model* (i.e., the relationship between predictors and social and occupational functioning) at both the single-predictor and the overall levels in order to explore potential predictors and delineate unique contributions. All analyses used a model-trimming approach through an iterative process in which non-significant paths with the smallest contribution were sequentially eliminated from a saturated model (where all variables were allowed to freely co-vary), until a best fitting model was derived to best

1  
2  
3 explain the relationships between predictors and functional impairment. Finally, modification  
4 indices generated by AMOS were used to optimise model fit (i.e., to inform which paths and  
5 parameters should be added or removed to increase model adequacy), although these were  
6 only used when deemed theoretically meaningful. Residuals were allowed to correlate if  
7 theoretically justified (e.g., common measurement variance between neuropsychological  
8 subtests).

9  
10  
11  
12  
13  
14  
15  
16 Model fit was determined using: (1) the absolute fit  $\chi^2$  statistic; and (2) the relative fit  
17 indices: Bentler comparative fit index (CFI<sup>36</sup>), Bentler-Bonnett non-normed fit index (NFI<sup>37</sup>)  
18 and Root Mean Square Error of Approximation (RMSEA<sup>38</sup>) with 90% confidence interval. An  
19 excellent-fitting model is typically indicated by a non-significant  $\chi^2$  test (indicating a non-  
20 significant difference between the covariance matrix of the data and the model), a CFI and  
21 NFI of greater than .90 (indicating that the current model was superior to a null model where  
22 all paths are constrained to zero), and a RMSEA of less than .05 with an upper confidence  
23 interval bound of less than .08 (indicating that the error of approximation of the model  
24 compared with the data was acceptable). In small samples (ie, less than 200), the  $\chi^2$  statistic  
25 has been shown to be an adequate index of absolute model fit.<sup>35</sup> However, as sample size  
26 increases, the  $\chi^2$  statistic (relative to a constant degrees of freedom; df) disproportionately  
27 increases, and is nearly always significant and inappropriately rejects the model irrespective  
28 of specified parameters.<sup>39 40</sup> An alternative solution is to compute a relative,  $\chi^2/df$  ratio, with a  
29 value between 2 and 5 considered excellent to adequate fit,<sup>39 41-43</sup> although primary emphasis  
30 will be placed on the relative fit indices as is the established convention.<sup>13</sup>

31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 Moderator analyses were conducted using the multiple-group analysis procedure in  
50 AMOS, which compares the parameter estimates between specified sub-groups to determine  
51 how predictors of social and occupational functioning in the final model are moderated by  
52 demographic and clinical factors (these were dichotomous to maintain statistical power within  
53  
54  
55  
56  
57  
58  
59  
60

sub-groups for this categorical procedure). We sought to specifically test whether predictors in affective-spectrum disorders (anxiety, depressive and bipolar disorders) were similarly associated with functional impairment compared with psychotic, developmental or behavioral conditions. We chose to include primary affective disorders (i.e. major depression, bipolar disorder or an anxiety disorder) as a moderator since these disorders have been shown to have carry less neurocognitive burden in recent-onset mood disorders<sup>44 45</sup> and, as such, could potentially influence the role of neurocognition and the magnitude of effects in the statistical models.

## RESULTS

### Sample Characteristics

In total, 1003 patients were recruited. As shown in Table 1, cross-sectional diagnoses comprised of depressive (n = 449), bipolar (n = 178), psychotics (n = 193), anxiety (n = 109), and developmental or behavioral disorders (n = 74). The mean age was 20.4 years (SD = 4.7), with 54.0% being female (n = 542). Mean educational attainment was 11.7 years (SD = 2.5), with an average predicted IQ of 101.9 (SD = 10.8). The mean SOFAS score was 61.2 (SD = 11.4), indicating moderate levels of impairment. Of the participants with medication data available (87.4%, n = 877), 64.8% were prescribed psychotropic medications (n = 568). Of these 568 cases, 40.6% were prescribed an antidepressant (n = 356), 14.8% were prescribed lithium or an anticonvulsant (n = 130), 33.1% were prescribed any antipsychotic (n = 290), and 4.8% were prescribed a stimulant (n = 42).

[Insert Table 1 about here]

### Single-Predictor Models

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44
- A. Neurocognition.** The best fitting factor structure for the neuropsychological measures was a one-factor model with all tests loading on a single latent variable. Factor loadings were all significant and ranged from 0.51 to 0.69 (see Figure 1A and legend). Neurocognition was a significant contributor to functional level ( $\beta = 0.39$ ,  $p < 0.001$ ), explaining 15% of the variance. This model was a good fit for the data ( $\chi^2 = 57.3$ ,  $df = 17$ ,  $p < 0.001$ , CFI = 0.980, NFI = 0.972, RMSEA = 0.055, 90% CI = 0.040–0.071).
- B. Core clinical symptom dimensions.** Only three dimensions [depression and anxiety ( $\beta = -0.18$ ,  $p < 0.001$ ), positive symptoms ( $\beta = -0.17$ ,  $p < 0.001$ ), and negative symptoms ( $\beta = -0.26$ ,  $p < 0.001$ )] were associated with functioning. The model demonstrated an excellent fit ( $\chi^2 = 8.6$ ,  $df = 8$ ,  $p < 0.379$ , CFI = 0.999, NFI = 0.986, RMSEA = 0.009, 90% CI = 0.000–0.043), with the three dimensions explaining a total of 18% of the variance in functioning (see Figure 1B).
- C. Alcohol and substance use.** A two-factor model emerged as the best fitting measurement model for alcohol and substance use, whereby tobacco, cannabis and other illicit substance use loaded on a single ‘substance use’ latent variable (Figure 1C and legend), as distinct from alcohol use. Only substance use was predictive of functioning ( $\beta = -0.10$ ,  $p < 0.05$ ), explaining 1% of the variance. The model was an excellent fit for the data ( $\chi^2 = 7.4$ ,  $df = 4$ ,  $p < 0.116$ , CFI = 0.995, NFI = 0.990, RMSEA = 0.033, 90% CI = 0.000–0.069).

45 [Insert Figure 1 about here]

## 46 47 48 **Final Model**

49  
50  
51 In the overall model, all the factors identified in the single predictor models remained  
52 significant, except for substance use (Figure 2). Neurocognition showed the strongest unique  
53 contribution to social and occupational functioning ( $\beta = 0.36$ ,  $p < 0.001$ ); depressive  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 symptoms were next ( $\beta = -0.24$ ,  $p < 0.001$ ), followed by negative symptoms ( $\beta = -0.15$ ,  $p <$   
4  $0.001$ ) and finally positive symptoms ( $\beta = -0.10$ ,  $p < 0.001$ ). Together, these four clinical  
5 features independently accounted for 31% of the variance in functioning, with the final model  
6 being a very good fit for the data ( $\chi^2 = 279.8$ ,  $df = 119$ ,  $p < 0.000$ ,  $CFI = 0.956$ ,  $NFI = 0.926$ ,  
7  $RMSEA = 0.037$ ,  $90\% CI = 0.031-0.042$ ). Mania, disorientation, and alcohol and substance  
8 use, all significantly correlated with these four significant features ( $p$ 's  $< 0.05$ ).

15  
16 [Insert Figure 2 about here]  
17

### 18 19 Moderator Analyses

- 20  
21 • *Age*. As shown in Table 2, positive symptoms were no longer a significant contributor to  
22 functioning in the 12- to 20-year-old group ( $\beta = -0.06$ ,  $p = 0.178$ ). The model with older  
23 individuals explained 18% more variance in functional impairment than the model with  
24 younger individuals. This was driven in large part by a difference in predictive strength of  
25 neurocognition, whereby it was more predictive in older ( $\beta = 0.44$ ,  $p < 0.001$ ) than  
26 younger individuals ( $\beta = 0.27$ ,  $p < 0.001$ ).
- 27  
28 • *Gender*. Positive symptoms were non-significant in the male sub-group ( $\beta = -0.07$ ,  $p =$   
29  $0.145$ ), whereas all other clinical features remained significant ( $p$ 's  $< 0.001$ ). In females,  
30 negative symptoms became non-significant ( $\beta = -0.07$ ,  $p = 0.105$ ), whilst the other  
31 contributors remained significant. The final model was comparable across genders in  
32 terms of the total variance explained.

33  
34  
35  
36  
37  
38  
39  
40  
41  
42 [Insert Table 2 about here]  
43

- 44  
45 • *Primary affective disorder diagnosis*. Neurocognition, depression and anxiety, and  
46 negative symptoms remained significant contributors to functional level irrespective of  
47 affective disorder diagnosis (see Table 3). By contrast, positive symptoms no longer  
48 remained significant in both the affective disorder ( $\beta = -0.63$ ,  $p = 0.097$ ) and psychosis,  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

developmental or behavioral disorders ( $\beta = -0.102$ ,  $p = 0.123$ ) sub-groups. An additional 14% of the variance in functioning was explained in individuals with a psychotic, developmental or behavioral disorder, primarily owing to the greater predictive strength of neurocognition (0.30 vs. 0.43,  $p$ 's  $< 0.001$ ).

- *Medication usage.* All factors associated with functional impairment remained significant in participants who were unmedicated. By contrast, positive symptoms no longer remained significant in medicated individuals ( $\beta = -0.06$ ,  $p = 0.117$ ).

[Insert Table 3 about here]

## DISCUSSION

In a large, clinical, transdiagnostic cohort of youth with early-stage mental disorders, impaired neurocognition was the clinical feature most significantly associated with functional impairment. The role of neurocognition was attenuated in those with an affective disorder diagnosis and in the youngest age group. The findings are relevant as they demonstrate that whilst neurocognitive impairment may undermine functioning in those with psychotic disorders, they are not specific to such cases.

Depressive, anxiety and negative symptom dimensions also contributed significantly to level of social and occupational functioning; findings which support previous disorder-specific research.<sup>11 13 27</sup> Importantly, the contributions of these factors to level of functioning were largely independent of one another, and do not appear to be moderated by other clinical or demographic factors. By comparison, the role of positive symptoms diminished considerably in the final model; this finding differs from other research in psychotic and bipolar disorders, and may reflect the lower prevalence of positive symptoms in our cohort in



1  
2  
3 contrast to previous studies.<sup>11 13 27</sup> However, it was notable that positive symptoms in older,  
4  
5 unmedicated females remained significantly associated with functioning.  
6

7  
8 Intriguingly, neither alcohol and substance use, nor sleep disturbances, were directly  
9  
10 associated with functional impairment, although these factors remained significantly  
11  
12 associated with neurocognition and clinical symptoms. Therefore, their role in social and  
13  
14 occupational functioning does not appear to be direct, but may operate indirectly (e.g.  
15  
16 substance use may impair cognition, which in turn may impair functioning). The indirect  
17  
18 effects of alcohol and substance use, as well as sleep and circadian disruptions, warrant more  
19  
20 detailed examination and causal analysis in longitudinal datasets.  
21  
22

23  
24 The current findings have important implications for the transdiagnostic, dimensional  
25  
26 approach to psychiatry. Research examining the underlying mechanisms of functional  
27  
28 impairment in single- or dual-diagnosis cohorts have been unable to capture the unique  
29  
30 contributions of a comprehensive range of neurocognitive, symptom, sleep and circadian  
31  
32 factors, as well as other psychoactive exposures (ie, substance use, prescribed medications).<sup>46</sup>  
33  
34 In particular, neuropsychological studies in older adults with chronic schizophrenia have not  
35  
36 routinely and concurrently assessed depression and anxiety symptoms, hypomania and full-  
37  
38 threshold mania, substance misuse, and sleep disturbance. That is not to say that categorical,  
39  
40 nosological approaches have had little to contribute to the field. Indeed, the key argument  
41  
42 underpinning a DSM-approach is to allow for comparability across studies and so diagnostic  
43  
44 determinations are often necessary. However, in youth diagnoses tend to be unstable<sup>1</sup> and, as  
45  
46 such, as not as useful. One plausible way forward for dimensional psychiatry is to ensure that  
47  
48 the samples used in transdiagnostic studies are characterised as clearly and as  
49  
50 comprehensively as possible,<sup>16 47 48</sup> as was attempted in the present investigation.  
51  
52  
53

54  
55 In terms of limitations, the current analyses were cross-sectional, and future research  
56  
57 investigating moderator and mediator analyses would benefit from cross-lagged, longitudinal  
58  
59  
60

1  
2  
3 path modelling to disentangle causality.<sup>49</sup> Secondly, the measures used to index alcohol and  
4  
5 substance use, as well as sleep and circadian disturbances, were not as comprehensive as is  
6  
7 typical in the addiction and sleep literatures. Future studies would benefit from including  
8  
9 more detailed questionnaires, as well as real-time tracking technologies (e.g. substance use  
10  
11 monitoring using smartphones, actigraphy monitoring of physical activity and sleep quality).  
12  
13 Thirdly, medication data were not available for the full sample (12.6% were missing) and, as  
14  
15 such, the moderating role of medication status requires further corroboration. Finally, a  
16  
17 phenotype-approach, as attempted in the current study, would necessarily require converging  
18  
19 genetic and neuroimaging evidence to ensure that the neurocognitive and symptom  
20  
21 dimensions identified as predictive of functioning are linked to specific neural circuitries (eg,  
22  
23 cortico-basal ganglia systems<sup>50</sup>) and genotype, which would ultimately facilitate the  
24  
25 development of next-generation and neuroscience-informed pharmacotherapies.  
26  
27  
28

29  
30 This was the first study to examine a broad range of illness-related factors and  
31  
32 associations with functional impairment in a well-powered and broadly transdiagnostic,  
33  
34 clinical cohort of more than one thousand young people with mental illness. A significant  
35  
36 contribution of the present findings to the established literature was evidence showing that  
37  
38 neurocognition is a strong and reliable, unique predictor of social and occupational  
39  
40 functioning irrespective of diagnosis – in a cohort predominantly comprised of affective  
41  
42 disorders, which has not been previously demonstrated before at this scale. As such, the  
43  
44 functional importance of neurocognitive functions clearly extends beyond the psychosis and  
45  
46 developmental disorders spectrum and appears to become more pronounced with increasing  
47  
48 age. Future studies should attempt to replicate these findings, as well as to clarify the  
49  
50 directions of cause and effect.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Author statement

RSCL, DFH, SLN, AJG, NG, JS, EMS and IBH contributed to the conception of the study; RSCL, DFH, MK undertook the data collection, processing and analysis; RSCL wrote the first draft of the manuscript. All authors contributed to data interpretation, discussion and have approved the final manuscript.

### Funding

This study was supported by a grant from the National Health & Medical Research Council (NHMRC) including: Centre of Research Excellence (No. 1061043). The funder had no input to study design, data collection/interpretation, writing, or submission for publication.

### Competing interests

(1) No authors have support from any company for the submitted work; (2) no authors have relationships with any company that might have an interest in the submitted work; (3) no author, their spouses, partners, or children have financial relationships that may be relevant to the submitted work and; (4) no authors have any non-financial interests that may be relevant to the submitted work.

### Ethical approval

This study was approved by the University of Sydney Human Research Ethics Committee (reference 12130; protocol no. 2012/1631).

### Availability of data and materials

The datasets generated and/or analysed during the current study are not publicly available due to the breadth and sensitivity of data collected, which may have implications for individual privacy, but are available from the corresponding author on reasonable request.

## REFERENCES

1. Bromet EJ, Kotov R, Fochtmann LJ, et al. Diagnostic shifts during the decade following first admission for psychosis. *American Journal of Psychiatry* 2011;168(11):1186-94. doi: 10.1176/appi.ajp.2011.11010048 [published Online First: 2011/06/17]
2. Hickie IB, Scott J, Hermens DF, et al. Clinical classification in mental health at the cross-roads: which direction next? *BMC medicine* 2013;11:125. doi: 10.1186/1741-7015-11-125 [published Online First: 2013/05/16]
3. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. *Australian and New Zealand Journal of Psychiatry* 2006;40(8):616-22.
4. Cross SPM, Hermens DF, Scott EM, et al. A Clinical Staging Model for Early Intervention Youth Mental Health Services. *Psychiatric Services* 2014;65(7):939-43. doi: 10.1176/appi.ps.201300221
5. Lee RSC, Redoblado MA, Naismith SL, et al. Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. *Psychological Medicine* 2013;43(6):1161-73.
6. Cross SPM, Scott J, Hickie IB. Predicting early transition from sub-syndromal presentations to major mental disorders. *BJPsych Open* 2017;3(5):223-27. doi: 10.1192/bjpo.bp.117.004721
7. Lee RSC, Hermens D, Scott J, et al. A Transdiagnostic Study of Education, Employment, and Training Outcomes in Young People with Mental Illness. *Psychological Medicine* 2017;47:2061–70.
8. O'Dea B, Lee RS, McGorry PD, et al. A prospective cohort study of depression course, functional disability, and NEET status in help-seeking young adults. *Soc Psychiatry Psychiatr Epidemiol* 2016 doi: 10.1007/s00127-016-1272-x [published Online First: 2016/08/09]
9. Davidson L, O'Connell MJ, Tondora J, et al. Recovery in Serious Mental Illness: A New Wine or Just a New Bottle? *Professional Psychology: Research and Practice* 2005;36(5):480-87. doi: 10.1037/0735-7028.36.5.480
10. World Health Organization. Mental Health Action Plan 2013-2020. Geneva, Switzerland: World Health Organization 2013.

11. Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: A comparison of schizophrenia and bipolar disorder. *The American Journal of Psychiatry* 2010;167(9):1116-24.
12. Lee RSC, Hermens DF, Redoblado MA, et al. Neuropsychological and socio-occupational functioning in young psychiatric outpatients: a longitudinal investigation. *PLOS ONE* 2013;8(3):e58176. doi: 10.1371/journal.pone.0058176
13. Galderisi S, Rossi A, Rocca P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2014;13(3):275-87. doi: 10.1002/wps.20167
14. Thomas ML, Green MF, Helleman G, et al. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. *JAMA psychiatry (Chicago, Ill)* 2017;74(1):37-46. doi: 10.1001/jamapsychiatry.2016.2980 [published Online First: 2016/12/08]
15. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *The Lancet* 2013 doi: [http://dx.doi.org/10.1016/S0140-6736\(13\)61611-6](http://dx.doi.org/10.1016/S0140-6736(13)61611-6)
16. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2014;13(1):28-35. doi: 10.1002/wps.20087
17. Robbins TW, Gillan CM, Smith DG, et al. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. *Trends in Cognitive Sciences* 2012;16(1):81-91. doi: 10.1016/j.tics.2011.11.009
18. Millan MJ, Agid Y, Brüne M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nature Reviews Drug Discovery* 2012;11(2):141-68.
19. Hägele C, Schlagenhaut F, Rapp M, et al. Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. *Psychopharmacology* 2015;232(2):331-41. doi: 10.1007/s00213-014-3662-7
20. Yee CM, Javitt DC, Miller GA. Replacing DSM Categorical Analyses With Dimensional Analyses in Psychiatry Research: The Research Domain Criteria Initiative. *JAMA*

- 1  
2  
3 *psychiatry (Chicago, Ill)* 2015;72(12):1159-60. doi: 10.1001/jamapsychiatry.2015.1900  
4 [published Online First: 2015/11/13]  
5
- 6 21. Miller GA. Mistreating Psychology in the Decades of the Brain. *Perspectives on*  
7 *psychological science : a journal of the Association for Psychological Science*  
8 2010;5(6):716-43. doi: 10.1177/1745691610388774 [published Online First:  
9 2011/09/29]  
10
- 11 22. Lee RSC, Hermens DF, Naismith SL, et al. Neuropsychological and functional outcomes  
12 in recent-onset major depression, bipolar disorder and schizophrenia-spectrum  
13 disorders: A longitudinal cohort study. *Translational Psychiatry* 2015;5:e555.  
14
- 15 23. Hermens D, Naismith S, Lagopoulos J, et al. Neuropsychological profile according to the  
16 clinical stage of young persons presenting for mental health care. *BMC Psychology*  
17 2013;1(1):8.  
18
- 19 24. Scott EM, Hermens DF, Glozier N, et al. Targeted primary care-based mental health  
20 services for young Australians. *Medical Journal of Australia* 2012;196:136-40.  
21
- 22 25. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures  
23 of social functioning. *American Journal of Psychiatry* 1992;149(9):1148-56.  
24
- 25 26. Lee RSC, Hermens DF, Redoblado-Hodge MA, et al. Neuropsychological and socio-  
26 occupational functioning in young psychiatric outpatients: a longitudinal investigation.  
27 *PLoS One* 2013;8 doi: 10.1371/journal.pone.0058176  
28
- 29 27. Green MF, Helleman G, Horan WP, et al. From perception to functional outcome in  
30 schizophrenia: modeling the role of ability and motivation. *Archives of General*  
31 *Psychiatry* 2012;69(12):1216-24. doi: 10.1001/archgenpsychiatry.2012.652 [published  
32 Online First: 2012/10/03]  
33
- 34 28. Strauss E, Sherman EMS, Spreen O. A Compendium of neuropsychological tests:  
35 Administration, norms, and commentary. 3rd ed. New York: Oxford University Press  
36 2006.  
37
- 38 29. Lezak MD, Howieson DB, Bigler ED, et al. Neuropsychological Assessment. 5th ed. ed.  
39 New York: Oxford University Press 2012.  
40
- 41 30. Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale -  
42 Expanded (BPRS-E) structure and arguments for a new version. *Journal of Psychiatric*  
43 *Research* 2016;81:140-51. doi: 10.1016/j.jpsychires.2016.07.001  
44
- 45 31. Londborg PD, Smith WT, Glaudin V, et al. Short-term cotherapy with clonazepam and  
46 fluoxetine: anxiety, sleep disturbance and core symptoms of depression. *Journal of*  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 *Affective Disorders* 2000;61(1–2):73-79. doi: <https://doi.org/10.1016/S0165->  
4 0327(99)00195-0  
5  
6  
7 32. Hamilton M. A rating scale for depression. *Journal of Neurology, Neurosurgery &*  
8 *Psychiatry* 1960;23(1):56-62.  
9  
10 33. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders  
11 Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons  
12 with Harmful Alcohol Consumption--II. *Addiction (Abingdon, England)*  
13 1993;88(6):791-804. [published Online First: 1993/06/01]  
14  
15 34. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement  
16 Screening Test (ASSIST): Development, reliability and feasibility. *Addiction*  
17 *(Abingdon, England)* 2002;97(9):1183-94. [published Online First: 2002/08/30]  
18  
19 35. Arbuckle JL. IBM SPSS Amos 20 User's Guide: IBM Corporation 2011.  
20  
21 36. Bentler PM. Comparative Fit Indexes in Structural Models. *Psychological Bulletin*  
22 1990;107(2):238-46.  
23  
24 37. Bentler PM, Bonett DG. Significance tests and goodness of fit in the analysis of  
25 covariance structures. *Psychological Bulletin* 1980;88(3):588-606.  
26  
27 38. Steiger JH. Tests for comparing elements of a correlation matrix. *Psychological Bulletin*  
28 1980;87(2):245-51.  
29  
30 39. Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation  
31 models: Tests of significance and descriptive goodness-of-fit measures. *Methods of*  
32 *Psychological Research-Online* 2003;8:23-74. doi: citeulike-article-id:7222182  
33  
34 40. Jöreskog K, Sörbom D. LISREL 8: Structural Equation Modeling with the SIMPLIS  
35 Command Language Chicago, IL: Scientific Software International Inc. 1993.  
36  
37 41. Wheaton B, Muthen B, Alwin D, et al. Assessing Reliability and Stability in Panel  
38 Models. *Sociological Methodology* 1977;8:84-136.  
39  
40 42. Tabachnick B, Fidell L. Using Multivariate Statistics (5th ed.). New York: Allyn and  
41 Bacon 2007.  
42  
43 43. Kline R. Principles and Practice of Structural Equation Modeling (2nd ed.) New York:  
44 The Guilford Press 2005.  
45  
46 44. Lee RSC, Hermens DF, Porter MA, et al. A meta-analysis of cognitive deficits in first-  
47 episode Major Depressive Disorder. *Journal of Affective Disorders* 2012;140(2):113-24.  
48 doi: 10.1016/j.jad.2011.10.023  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 45. Lee RSC, Hermens DF, Scott J, et al. A meta-analysis of neuropsychological functioning  
4 in first-episode bipolar disorders. *Journal of Psychiatric Research* 2014;57:1-11. doi:  
5 10.1016/j.jpsychires.2014.06.019  
6  
7  
8 46. Iorfino F, Hickie IB, Lee RSC, et al. The underlying neurobiology of key functional  
9 domains in young people with mood and anxiety disorders: a systematic review. *BMC*  
10 *Psychiatry* 2016;16(1):1-38. doi: 10.1186/s12888-016-0852-3  
11  
12 47. Casey BJ, Craddock N, Cuthbert BN, et al. DSM-5 and RDoC: progress in psychiatry  
13 research? *Nature reviews Neuroscience* 2013;14(11):810-14. doi: 10.1038/nrn3621  
14  
15 48. Craddock N, Owen MJ. Rethinking psychosis: the disadvantages of a dichotomous  
16 classification now outweigh the advantages. *World psychiatry : official journal of the*  
17 *World Psychiatric Association (WPA)* 2007;6(2):84-91. [published Online First:  
18 2008/02/01]  
19  
20 49. Breitborde NJ, Srihari VH, Pollard JM, et al. Mediators and moderators in early  
21 intervention research. *Early Interv Psychiatry* 2010;4(2):143-52. doi: 10.1111/j.1751-  
22 7893.2010.00177.x [published Online First: 2010/06/12]  
23  
24 50. Griffiths KR, Lagopoulos J, Hermens DF, et al. Impaired causal awareness and associated  
25 cortical–basal ganglia structural changes in youth psychiatric disorders. *NeuroImage:*  
26 *Clinical* 2016;12:285-92. doi: <http://dx.doi.org/10.1016/j.nicl.2016.06.017>  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1** Demographic, clinical and functional characteristics across diagnostic sub-groups

	ANXIETY <sup>1</sup> (n = 109)		DEPRESSION <sup>2</sup> (n = 449)		BIPOLAR <sup>3</sup> (n = 178)		PSYCHOSIS <sup>4</sup> (n = 193)		DEV/BEHAV <sup>5</sup> (n = 74)	
	M	SD	M	SD	M	SD	M	SD	M	SD
Age	19.9	4.8	19.8	4.3	21.6	4.8	22.2	4.6	17.0	4.6
Education (years)	11.5	2.7	11.6	2.4	12.3	2.2	12.0	2.4	10.0	2.8
Premorbid IQ	102.7	9.6	103.3	10.5	102.8	9.1	100.0	10.5	95.3	14.8
BPRS Depression (/7)	2.3	0.9	2.4	0.8	2.2	0.8	2.1	0.9	1.7	0.7
BPRS Mania (/7)	1.4	0.4	1.3	0.5	1.5	0.6	1.4	0.4	1.5	0.7
BPRS Positive (/7)	1.4	0.5	1.3	0.4	1.4	0.5	1.8	0.7	1.3	0.4
BPRS Negative (/7)	1.5	0.7	1.5	0.6	1.3	0.5	1.9	0.8	1.5	0.6
BRPS Disorientation (/7)	1.2	0.5	1.2	0.5	1.1	0.5	1.2	0.6	1.2	0.5
HDRS Sleep (/6)	1.5	1.5	2.0	1.8	1.7	1.7	1.3	1.6	1.8	1.7
AUDIT Alcohol Use (/40)	4.4	6.4	6.8	7.4	9.0	8.4	6.2	8.0	5.1	7.5
WHO-ASSIST Tobacco Use (/4)	1.0	1.5	1.3	1.6	1.6	1.7	1.7	1.9	1.4	1.7
WHO-ASSIST Cannabis Use (/4)	0.4	0.9	0.7	1.2	0.7	1.3	0.4	1.0	0.7	1.3
WHO-ASSIST Other Illicit Substance Use (/4)	0.1	0.3	0.1	0.3	0.1	0.3	0.1	0.2	0.1	0.3
SOFAS	63.2	11.1	61.8	10.7	63.9	11.5	55.9	12.1	61.7	9.8
	N	%	N	%	N	%	N	%	N	%
Gender (female)	58	53.2	277	61.7	129	72.5	58	30.1	20	27.0
Medicated <sup>†</sup>	37	45.7	231	60.0	128	77.6	140	77.3	32	49.2
Antidepressants	25	30.9	201	52.2	63	38.2	55	30.4	12	18.5
Lithium/Anticonvulsants	6	7.4	28	7.3	69	41.8	24	13.3	3	4.6
Antipsychotics	9	11.1	71	18.4	77	46.7	125	69.1	8	12.3
Stimulants	4	4.9	14	3.6	7	4.2	3	1.7	14	21.5

AUDIT–Alcohol Use Disorders Identification Test; BPRS–Brief Psychiatric Rating Scale; DEV/BEHAV– Developmental/Behavioral; HDRS–Hamilton Depression Rating Scale; SOFAS– Social and Occupational Functioning Assessment Scale; WHO-ASSIST–World Health Organization – Alcohol, Smoking and Substance Involvement Screening Test

<sup>1</sup> Panic Disorder (n=4), Social Phobia (n=29), Obsessive–Compulsive Disorder (n=11), Posttraumatic Stress Disorder (n=5), Generalised Anxiety Disorder (n=60)

<sup>2</sup> Major Depressive Disorder (n=313), Dysthymic Disorder (n=4), Depressive Disorder Not Otherwise Specified (n=132)

<sup>3</sup> Bipolar I Disorder (n=13), Bipolar II Disorder (n=25), Cyclothymic Disorder (n=1), Bipolar Disorder Not Otherwise Specified (n=139)

<sup>4</sup> Schizophrenia (n=53), Schizophreniform Disorder (n=15), Schizoaffective Disorder (n=26), Brief Psychotic Disorder (n=11), Substance-Induced Psychotic Disorder (n=14), Psychotic Disorder Not Otherwise Specified (n=74)

<sup>5</sup> Asperger’s Disorder (n=16), Attention-Deficit/Hyperactivity Disorder (n=47), Conduct Disorder (n=7), Oppositional Defiant Disorder (n=4)

<sup>†</sup> Medication data was available in 877 individuals (87.4%), with missing data for the typologies of Depression (n=64), Bipolar (n=13), Psychosis (n=12), Anxiety (n=28), Developmental (n=9)

**Table 2** Analyses of age and gender as moderators of the relationships between neurocognition, core clinical symptoms and functioning

	Age <sup>†</sup>				Gender <sup>‡</sup>			
	12-20 Years (n = 539)		21-36 Years (n = 464)		Male (n = 461)		Female (n = 542)	
	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value
<b>Neurocognition</b>	.27	.000	.44	.000	.35	.000	.35	.000
<b>Depression and Anxiety</b>	-.28	.000	-.22	.000	-.23	.000	-.30	.000
<b>Positive Symptoms</b>	-.06	.178	-.14	.002	-.07	.145	-.12	.004
<b>Negative Symptoms</b>	-.13	.005	-.18	.000	-.19	.000	-.07	.105

<sup>†</sup> 12-20 Years (Subgroup Model,  $R^2=.24$ ); 21-36 Years (Subgroup Model,  $R^2=.40$ )

<sup>‡</sup> Male (Subgroup Model,  $R^2=.32$ ); Female (Subgroup Model,  $R^2=.29$ )

**Table 3** Analyses of primary affective disorder and medication usage as moderators of the relationship between neurocognition, core clinical symptoms and functioning

	Primary Affective Disorder <sup>†</sup>				Medication Usage <sup>‡</sup>			
	Yes (n = 736)		No (n = 267)		Nil (n = 309)		Medicated (n = 568)	
	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value
<b>Neurocognition</b>	.30	.000	.43	.000	.38	.000	.38	.000
<b>Depression and Anxiety</b>	-.29	.000	-.24	.000	-.15	.007	-.24	.000
<b>Positive Symptoms</b>	-.06	.097	-.10	.123	-.22	.000	-.06	.117
<b>Negative Symptoms</b>	-.12	.003	-.16	.009	-.19	.000	-.13	.002

<sup>†</sup> Yes (Subgroup Model,  $R^2=.24$ ); No (Subgroup Model,  $R^2=.38$ )

<sup>‡</sup> Nil (Subgroup Model,  $R^2=.38$ ); Medicated (Subgroup Model,  $R^2=.29$ )

1  
2  
3 **Figure 1** Combined measurement and structural models for functioning and (A)  
4 neurocognition, (B) core clinical symptoms, and (C) alcohol and substance use.  
5

6 *Legend:*

7 All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except  
8 path between substance use and functional outcome; where  $p < .05$ )

9 Factor Loadings for (A) Neurocognition (all  $p$ 's  $< .001$ ): IQ (.58), Trails A (-.51), Trails B (-.55), Rey  
10 Total (.69), Rey Delay (.59), FAS (.57), Animals (.51)

11 Factor Loadings for (C) Substance Use (all  $p$ 's  $< .001$ ): Tobacco (.81), Cannabis (.64), Other (.68)  
12  
13  
14

15 **Figure 2** Final model.

16  
17 *Legend:*

18 All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except  
19 correlation between substance use and positive symptoms, where  $p < .05$ ). Where no path is drawn it  
20 denotes no significant relationship between the variables (see Figure 1 for all factor loadings of latent  
21 variables).  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Combined measurement and structural models for functioning and (A) neurocognition, (B) core clinical symptoms, and (C) alcohol and substance use.

#### Legend:

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except path between substance use and functional outcome; where  $p < .05$ )

Factor Loadings for (A) Neurocognition (all  $p$ 's  $< .001$ ): IQ (.58), Trails A (-.51), Trails B (-.55), Rey Total (.69), Rey Delay (.59), FAS (.57), Animals (.51)

Factor Loadings for (C) Substance Use (all  $p$ 's  $< .001$ ): Tobacco (.81), Cannabis (.64), Other (.68)

230x199mm (144 x 144 DPI)




Figure 2 Final model.

Legend:

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except correlation between substance use and positive symptoms, where  $p < .05$ ). Where no path is drawn it denotes no significant relationship between the variables (see Figure 1 for all factor loadings of latent variables).

393x208mm (144 x 144 DPI)

**STROBE Statement**—checklist of items that should be included in reports of observational studies

RE: “*A cross-sectional study of clinical, neurocognitive, and demographic factors associated with functional impairment in the Brain and Mind Youth Cohort*”

	Item No	Recommendation	Authors Response
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract <b>Pg. 1</b>	Yes
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found <b>Pg. 2</b>	Yes
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <b>Pg. 4-6</b>	Yes
Objectives	3	State specific objectives, including any prespecified hypotheses <b>Pg. 6</b>	Yes
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper <b>Pg. 6-7</b>	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <b>Pg. 7</b>	Yes
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants <b>Pg. 7</b>	Yes
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <b>Pg. 7-11</b>	Yes
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <b>Pg. 8</b>	Yes
Bias	9	Describe any efforts to address potential sources of bias <b>Pg. 10-11</b>	Yes
Study size	10	Explain how the study size was arrived at <b>Pg. 10</b>	Yes
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <b>Pg. 9-11</b>	Yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <b>Pg. 9-11</b>	Yes
		(b) Describe any methods used to examine subgroups and interactions <b>Pg. 10-11</b>	Yes
		(c) Explain how missing data were addressed <b>Pg. 9</b>	Yes
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls	NA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

was addressed

~~Cross-sectional study~~—If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses

NA

Continued on next page

For peer review only



Results			Authors Response
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <a href="#">Pg. 11</a>	Yes
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <a href="#">Pg. 11</a>	Yes
		(b) Indicate number of participants with missing data for each variable of interest <a href="#">Pg. 9</a>	Yes
		© <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<del><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</del>	Yes
		<del><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</del>	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures <a href="#">Pg. 11</a>	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <a href="#">Pg. 12-13</a>	Yes
		(b) Report category boundaries when continuous variables were categorized <a href="#">Pg. 10-11</a>	Yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses <a href="#">Pg. 11-14</a>	Yes
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives <a href="#">Pg. 14-15</a>	Yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <a href="#">Pg. 15-16</a>	Yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <a href="#">Pg. 14-16</a>	Yes
Generalisability	21	Discuss the generalisability (external validity) of the study results <a href="#">Pg. 16</a>	Yes
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <a href="#">Pg. 17</a>	Yes

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
2 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
3 available at [www.strobe-statement.org](http://www.strobe-statement.org).  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## A cross-sectional study of clinical, neurocognitive, and demographic factors associated with functional impairment in the Brain and Mind Youth Cohort

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022659.R1
Article Type:	Research
Date Submitted by the Author:	06-Aug-2018
Complete List of Authors:	Lee, Rico; Monash University School of Psychological Sciences Hermens, Daniel; Brain & Mind Research Institute , Naismith, Sharon; Brain & Mind Research Institute, Kaur, Manreena; Monash Alfred Psychiatry Research Centre Guastella, Adam; Brain & Mind Research Institute, Clinical Research Unit Glozier, Nick; Brain & Mind Research Institute, Clinical Research Unit Scott, Jan; Newcastle University, Institute of Neuroscience Scott, Elizabeth; Brain & Mind Research Institute, Hickie, Ian; The University of Sydney, Brain and Mind Centre;
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Mental health
Keywords:	neurocognition, transdiagnostic, functional impairment, mental illness, symptom dimensions, alcohol use

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6 **A CROSS-SECTIONAL STUDY OF CLINICAL, NEUROCOGNITIVE, AND**  
7  
8 **DEMOGRAPHIC FACTORS ASSOCIATED WITH FUNCTIONAL**  
9  
10 **IMPAIRMENT IN THE BRAIN AND MIND YOUTH COHORT**  
11  
12  
13  
14  
15

16 Rico S C Lee<sup>1,2</sup>, Daniel F Hermens<sup>ψ1</sup>, Sharon L Naismith<sup>1,3</sup>, Manreena Kaur<sup>1,4</sup>, Adam J Guastella<sup>1</sup>,  
17 Nick Glozier<sup>1,5</sup>, Jan Scott<sup>6,7</sup>, Elizabeth M Scott<sup>1</sup>, Ian B Hickie<sup>1</sup>  
18  
19  
20  
21  
22  
23

24 <sup>1</sup> Brain and Mind Centre, University of Sydney, Australia  
25

26 <sup>2</sup> Brain and Mental Health Research Hub, Monash University, Australia  
27

28 <sup>3</sup> Charles Perkins Centre, University of Sydney, Australia  
29

30 <sup>4</sup> The Monash Alfred Psychiatry Research Centre, Monash University, Australia  
31

32 <sup>5</sup> Marie Bashir Institute, University of Sydney, Australia  
33

34 <sup>6</sup> Academic Psychiatry, Institute of Neuroscience, Newcastle University, UK  
35

36 <sup>7</sup> Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, UK  
37  
38  
39  
40  
41  
42  
43  
44

45 Abstract word count: 243  
46

47 Manuscript word count: 4371  
48

49 Tables and figures: 4 tables, 2 figures  
50  
51  
52  
53

54  
55 <sup>ψ</sup> Corresponding author: Dr Rico S. C. Lee, Monash Biomedical Imaging, 770 Blackburn Rd,  
56 Clayton VIC, 3800; Phone: +61 3 9902 9808; Email: rico.lee@monash.edu.  
57  
58  
59  
60

## ABSTRACT

**Objectives:** We sought to determine the unique and shared contributions of clinical, neurocognitive and demographic factors to functional impairment in a large, transdiagnostic, clinical cohort of adolescents and young adults.

**Design:** Cross-sectional baseline data from a prospective, cohort study.

**Setting:** Help-seeking youth referred from outpatient services were recruited to the *Brain and Mind Youth Cohort* (2008-2016) in Sydney, Australia.

**Participants:** In total, 1003 outpatients were recruited, aged between 12 and 36 years (M = 20.4 years, 54% female), with baseline diagnoses of affective, psychotic, developmental or behavioural disorders.

**Interventions:** Treatment as usual.

**Primary outcome measures:** Social and occupational functioning was used to index level of functional impairment. Structural equation modelling was used to examine associations between neurocognition, core clinical symptoms, and alcohol and substance use, and clinician- and researcher-rated functional impairment. Moderator analyses were conducted to determine the potential influence of demographic and clinical factors (e.g. medication exposure).

**Results:** Independent of diagnosis, we found that neurocognitive impairments, and depressive, anxiety and negative symptoms, were significantly associated with functioning. The association of neurocognition with social and occupational functioning remained significant even when constraining age (only 15- to 25-year olds) or diagnosis (affective disorder) in the final model.

**Conclusions:** This study demonstrates that, in a clinically representative sample of youth, the key determinants of functioning may not be disorder specific. Further, evidence of neurocognitive

dysfunction suggests that interventions that target cognition and functioning should not necessarily be reserved only for older adults with established illness.

**Keywords:** Neurocognition; transdiagnostic; functional impairment; mental illness; symptom dimensions; alcohol use.

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- This was one of the largest studies to date ( $N > 1,000$ ) to examine the associations between a broad range of illness characteristics and functional impairment in a mostly adolescent and young adult, clinical sample.
- Given the transdiagnostic approach, this study was equipped to disentangle the shared and unique associations between core illness phenotypes and functional impairment across a range of common mental disorders.
- The use of latent-variable, structural equation modelling controlled for aspects of measurement imprecision.

## INTRODUCTION

In recent decades, early intervention services for youth with emerging mental disorders have extended their targets beyond those at risk of psychosis to also encompass those presenting with mood as well as other developmental and anxiety disorders. This approach creates several significant challenges. For example, some youth with depressive and anxiety disorders will ultimately develop psychotic or bipolar disorders; likewise, only a proportion of those receiving a diagnosis of bipolar disorders will consistently receive this diagnosis over the following 10 years.<sup>1</sup> The lack of diagnostic stability in help-seeking youth reflects the evolving disease process and means that the illness trajectory is less certain than for older adults with established illness.<sup>2 3</sup> From a research perspective, the use of dimensional approaches to phenomenology has helped us to understand illness progression in these early clinical stages, whilst from a clinical perspective, care and treatment have increasingly considered transdiagnostic interventions addressing core factors that may influence prognosis irrespective of cross-sectional diagnosis (e.g., anxiety, depressive or negative symptoms; sleep disturbances).<sup>4 5</sup> These approaches have highlighted that, in youth, a more meaningful measure of outcome may be functioning rather than change in diagnosis-specific symptoms. There is evidence to support this approach as level of functioning or disengagement (e.g., not being in education, employment or training, referred to as being NEET) is associated with early transition to major mental disorder<sup>6</sup> and with poor outcome of acute illness episodes.<sup>7 8</sup> However, to optimize interventions that target functioning it is important to understand the factors that contribute to level of functioning at clinical presentation. For instance, as well as transdiagnostic symptom dimensions, it is likely that other factors such as neurocognitive functioning and alcohol or substance use will also affect overall functioning. Disentangling the contribution and magnitude of any effects of these factors on functioning is important to determine which factors may be amenable to modification and allow clinicians to design a multidimensional intervention package.

1  
2 The proposal that social and occupational functioning should be a primary target for mental  
3 health interventions is not new and is increasingly promoted for older adults with established  
4 illness. For example, senior policy experts in the U.S. have stipulated that recovery-oriented  
5 treatments should form the overarching goal of mental health care and the foundation of strategic  
6 health policy.<sup>9</sup> The recognition that more personalized interventions are urgently needed to enhance  
7 functioning and quality of life rather than simply targeting diagnosis-specific symptoms is also  
8 emphasized by the World Health Organization.<sup>10</sup> Given this interest in enhancement of functioning  
9 across all stages of mental illness and for youth and adults presenting to mental health services, it is  
10 also useful to examine the role of other, key clinical (e.g., medication exposure) and demographic  
11 factors (e.g., age, gender) in determining functioning, which would contribute to prognosis and  
12 attempts at personalised medicine.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

26 Most path modelling studies to date have used small, single- or dual-diagnosis cohorts,  
27 predominantly in individuals with a chronic mental illness. Findings consistently demonstrate that  
28 neurocognition and negative symptoms are robust predictors of functional outcome in schizophrenia  
29 and bipolar disorder.<sup>7 11 12</sup> By contrast, the impact of affective and positive symptoms on  
30 functioning remains more equivocal. More recently, these findings have been replicated in large  
31 cohort studies,<sup>13 14</sup> although the vast majority of existing studies have focused exclusively on  
32 schizophrenia. There have been no well-powered studies examining a mental disorder other than  
33 schizophrenia, such as affective disorders, despite depression being the leading cause of disability  
34 worldwide.<sup>15</sup> Studies have also largely sidestepped the issue of psychotropic medication use.  
35 Furthermore, given that more than 75% of mental illnesses emerge before the age of 25,<sup>3</sup> examining  
36 younger cohorts is critically important for the development of novel approaches to early  
37 intervention since most studies to date have targeted older individuals.<sup>15</sup>  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51

52 In order to build upon prior research, a transdiagnostic and dimensional approach is ideally  
53 positioned to disentangle the factors associated with functioning. Key to this research strategy is the  
54 examination of shared constructs (e.g., neurocognition) with clear links to pathophysiology,<sup>16-18</sup>  
55  
56  
57  
58  
59  
60



1 which can inform novel therapeutics that target specific neural circuitries.<sup>17 19</sup> Transdiagnostic  
2 studies are also able to harness the variance across disorders, with the goal of developing robust,  
3  
4 unifying models that are *explanatory* in nature.<sup>2</sup> Data showing that physiological and genetic risk  
5  
6 factors for mental illness extend across, rather than are bound by, traditional diagnoses,<sup>20</sup> further  
7  
8 supports this paradigm, as does the frequent prescription of psychotropic medications for off-label  
9  
10 use across diagnostic boundaries.<sup>21</sup> Transdiagnostic studies are also superior to single-diagnosis  
11  
12 case-control studies in that they can determine which relationships are *shared* across various  
13  
14 diagnoses and which are *unique* to a particular disorder.  
15  
16  
17

18  
19 In this study, we sought to determine whether: (i) neurocognition; (ii) core clinical  
20  
21 dimensions; and (iii) alcohol and substance use, are associated with social and occupational  
22  
23 functioning and the magnitude of these associations. The rationale for examining clinical symptoms  
24  
25 and functioning alongside neurocognition, sleep changes, and substance use, is underscored by a  
26  
27 recent systematic review highlighting the transdiagnostic relevance of these key domains in youth  
28  
29 with mental illness.<sup>22</sup> In keeping with prior research,<sup>7 12 23</sup> it was hypothesized that neurocognition  
30  
31 and negative symptoms would make the greatest contribution to level of social and occupational  
32  
33 functioning irrespective of the cross-sectional diagnosis applied to cases at the time of inclusion in  
34  
35 the cohort. Given the high degree of heterogeneity expected in a transdiagnostic youth sample, we  
36  
37 secondarily sought to determine the influence of demographic (e.g., age, gender) and clinical factors  
38  
39 (e.g., diagnosis, medication exposure) on findings.  
40  
41  
42  
43  
44  
45

## 46 **METHODS**

47  
48 This study was approved by the University of Sydney Human Research Ethics Committee. Data  
49  
50 included in the current study represent the baseline assessments conducted at entry to the cohort  
51  
52 study, and were collected between April 2008 and May 2016.  
53  
54  
55  
56  
57  
58  
59  
60

## Participants

Participants were recruited into the Brain and Mind Youth Cohort from youth mental health outpatient services at the Brain and Mind Centre.<sup>24 25</sup> Referred participants were 12–36 years of age and presented with a major affective, psychotic or developmental/behavioral syndrome. Participants were excluded if they (or their guardians, if aged under 16 years) were unwilling or unable to provide written informed consent, or if they had a pre-existing neurological condition, clinically assessed impaired English language skills and/or intellectual disability that precluded completion of study self-ratings. Eligible participants completed a series of observer and self-rated questionnaires.

## Procedure

Treating clinicians recorded clinical diagnoses and these were reviewed at consensus meetings by senior, treating psychiatrists (e.g., IBH, EMS) and formal diagnoses recorded based on the DSM-IV-TR (Table 1 provides details of diagnoses and sample characteristics). Any disagreements in diagnosis were resolved at these consensus meetings with the relevant treating team. All participants received their prescribed course of medications and interventions, as independently determined in consultation with their treating clinicians.

Board-certified treating clinicians (i.e., consultant psychiatrists, clinical psychologists, mental health nurses) provided an evaluation of each participant's social and occupational functioning. Next, board-certified clinical psychologists, clinical neuropsychologists, or trained research psychologists (i.e., graduate-level academic psychologists; supervised by RSCL to ensure a sufficient level of inter-rater reliability), conducted structured clinical interviews, neuropsychological testing, as well as an additional assessment of social and occupational functioning to improve the reliability of this single, clinician-rated score (approximately 80% were conducted within a month of the treating clinician assessment).

## Measures

- *Social and occupational functioning* was indexed using the Social and Occupational Assessment Functioning Scale (SOFAS<sup>26</sup>). Scores were averaged across the treating clinician and researcher assessments (ICC = 0.70), as previously done.<sup>27</sup> This composite score was derived to obtain a more reliable estimate of real-world functioning and, secondarily, to conserve free parameters and increase stability of parameter estimates.<sup>23 28</sup> A higher score denotes better functioning.
- *Neurocognition* was assessed using a broad neuropsychological battery with demographic normative-adjustments (previously described<sup>23</sup>), and was chosen on the basis of sound psychometric properties<sup>29</sup> and relevance to the disorders under study.<sup>30</sup> Predicted IQ was estimated using the Wechsler Test of Adult Reading (WTAR) or Wide Range Achievement Test—fourth edition (WRAT-4, for participants younger than 16 years). Psychomotor speed and mental flexibility were measured using Trail Making Test—Part A (TMT-A) and -Part B (TMT-B). Verbal learning and memory were indexed using the five-trial total and delayed recall scores from the Rey Auditory Verbal Learning Test (RAVLT). Verbal fluency was comprised of the letter (FAS) and category (animals) fluency subtests of the Controlled Oral Word Association Test. A higher score indicates better functioning.
- *Core clinical symptom dimensions* were measured across two validated scales. Symptoms were rated on the expanded Brief Psychiatric Rating Scale (BPRS) using empirically-derived symptom sub-scores (depression and anxiety, mania, positive symptoms, negative symptoms, and disorientation<sup>31</sup>). The BPRS does not capture sleep profiles as a separate dimension so, as in previous studies,<sup>32</sup> disturbed sleep was indexed using the sum of the three sleep items from the Hamilton Depression Rating Scale (HDRS<sup>33</sup>). A higher score denotes greater severity of symptoms.

- *Alcohol and substance use* were measured across two validated scales. Alcohol use was indexed using the Alcohol Use Disorders Identification Test (AUDIT<sup>34</sup>) total score. Substance use for tobacco, cannabis, and other illicit substances was measured using the ‘current frequency’ sub-scale (past 3 months) from the World Health Organization – Alcohol, Smoking and Substance Involvement Screening Test (WHO-ASSIST) questionnaire.<sup>35</sup> A higher score indicates greater alcohol or substance use.

### **Patient and public involvement**

Participants were not involved in the development of research question(s), design and outcome measures, nor was the study informed by their priorities, experience, and preferences. We did not formally assess the burden of time required to participate in the research.

### **Data Analysis**

Statistical analyses were conducted using IBM SPSS 20.0 and AMOS 20.0. Maximum likelihood estimation (MLE) was employed for all structural equation modelling (SEM) analyses. MLE was chosen as it is the most robust approach in the potential event of statistical assumption violations and performs best in heterogeneous samples<sup>36</sup>. Missing data was also handled by MLE, which does not involve data imputation, but uses all available data to compute maximum likelihood estimates. Diagnostic and demographic data were available for all participants. In total, 9.1% of data were missing for functioning, 18.8% for neurocognition, 12.7% for clinical symptoms and disturbed sleep, and 17.7% were missing for alcohol and substance use. Each analysis had >80% of cases with complete data. Normality was assessed through inspection of Q-Q plots, given inferential measures of non-normality (e.g., Shapiro-Wilk statistic) are overly sensitive in large datasets and almost always return a significant finding<sup>37</sup>. All endogenous variables (e.g., SOFAS) met normality assumptions on visual inspection.

We first used SEM to evaluate the best-fitting *measurement model* for the following predictors: 1/ neurocognition; 2/ clinical symptoms and disturbed sleep; and 3/ alcohol and substance use. Then, we used SEM to test the *structural model* (i.e., the relationship between predictors and social and occupational functioning) at both the single-predictor and the overall levels in order to explore potential predictors and delineate unique contributions. This was done in a two-step process – first, by testing individual predictors and then by testing the combined predictors - to quantify the amount of overlapping and unique explanatory power. All analyses used a model-trimming approach through an iterative process in which non-significant paths with the smallest contribution were sequentially eliminated from a saturated model (where all variables were allowed to freely co-vary), until a best fitting model was derived to best explain the relationships between predictors and functional impairment. Finally, modification indices generated by AMOS were used to optimise model fit (i.e., to inform which paths and parameters should be added or removed to increase model adequacy), although these were only used when deemed theoretically meaningful. Residuals were allowed to correlate if theoretically justified (e.g., common measurement variance between neuropsychological subtests).

Model fit was determined using: (1) the absolute fit  $\chi^2$  statistic; and (2) the relative fit indices: Bentler comparative fit index (CFI<sup>38</sup>), Bentler-Bonnett non-normed fit index (NFI<sup>39</sup>) and Root Mean Square Error of Approximation (RMSEA<sup>40</sup>) with 90% confidence interval. An excellent-fitting model is typically indicated by a non-significant  $\chi^2$  test (indicating a non-significant difference between the covariance matrix of the data and the model), a CFI and NFI of greater than .90 (indicating that the current model was superior to a null model where all paths are constrained to zero), and a RMSEA of less than .05 with an upper confidence interval bound of less than .08 (indicating that the error of approximation of the model compared with the data was acceptable). In small samples (i.e., less than 200), the  $\chi^2$  statistic has been shown to be an adequate index of absolute model fit.<sup>36</sup> However, as sample size increases, the  $\chi^2$  statistic (relative to a constant degrees of freedom; df) disproportionately increases, and is nearly always significant and

1 inappropriately rejects the model irrespective of specified parameters.<sup>41 42</sup> An alternative solution is  
2 to compute a relative,  $\chi^2/df$  ratio, with a value between 2 and 5 considered excellent to adequate  
3  
4 fit,<sup>41 43-45</sup> although primary emphasis will be placed on the relative fit indices as is the established  
5  
6 convention.<sup>13</sup>  
7  
8  
9

10 Moderator analyses were conducted allowing a model to be tested in separate sub-groups,  
11 comparing the parameter estimates to determine how predictors of social and occupational  
12 functioning in the final model are moderated by demographic and clinical factors (these were  
13 dichotomous to maintain statistical power within sub-groups for this categorical procedure). For  
14 instance, the median-split on age was performed to determine whether the model held for both  
15 younger and older individuals whilst maintaining statistical power. We sought to specifically test  
16 whether predictors in affective-spectrum disorders (anxiety, depressive and bipolar disorders) were  
17 similarly associated with functional impairment compared with psychotic, developmental or  
18 behavioral conditions. We chose to include primary affective disorders (i.e. major depression,  
19 bipolar disorder or an anxiety disorder) as a moderator since these disorders have been shown to  
20 have carry less neurocognitive burden in recent-onset mood disorders<sup>46 47</sup> and, as such, could  
21 potentially influence the role of neurocognition and the magnitude of effects in the statistical  
22 models.  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

## 42 RESULTS

### 43 Sample Characteristics

44 In total, 1003 patients were recruited. As shown in Table 1 and 2, cross-sectional diagnoses  
45 comprised of depressive (n = 449), bipolar (n = 178), psychotic (n = 193), anxiety (n = 109), and  
46 developmental or behavioral disorders (n = 74). The mean age was 20.4 years (SD = 4.7), with  
47 54.0% being female (n = 542). Mean educational attainment was 11.7 years (SD = 2.5), with an  
48 average predicted IQ of 101.9 (SD = 10.8). The mean SOFAS score was 61.2 (SD = 11.4),  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 indicating moderate levels of impairment. Of the participants with medication data available  
2 (87.4%, n = 877), 64.8% were prescribed psychotropic medications (n = 568). Of these 568 cases,  
3 40.6% were prescribed an antidepressant (n = 356), 14.8% were prescribed lithium or an  
4 anticonvulsant (n = 130), 33.1% were prescribed any antipsychotic (n = 290), and 4.8% were  
5 prescribed a stimulant (n = 42).  
6  
7  
8  
9  
10  
11

12 [Insert Table 1 about here]  
13  
14  
15  
16  
17

### 18 **Single-Predictor Models**

- 19  
20  
21 **A. Neurocognition.** Inspecting the scree plot, exploratory factor analyses identified two potential  
22 latent structures. The one-factor model was a very good fit for the data ( $\chi^2 = 57.3$ ,  $df = 17$ ,  $p <$   
23  $0.001$ ,  $CFI = 0.980$ ,  $NFI = 0.972$ ,  $RMSEA = 0.055$ ,  $90\% CI = 0.040-0.071$ ), and was a better  
24 fit than a two-factor model, whereby Trails A, Trails B and IQ loaded on one latent factor, and  
25 IQ, Rey Total, Rey Delay, FAS and Animals loaded on a second latent factor ( $\chi^2 = 76.499$ ,  $df$   
26  $= 11$ ,  $p < 0.001$ ,  $CFI = 0.967$ ,  $NFI = 0.962$ ,  $RMSEA = 0.077$ ,  $90\% CI = 0.061-0.094$ ). Factor  
27 loadings on the one-factor model were all significant and ranged from 0.51 to 0.69 (see Figure  
28 1A and legend). Neurocognition was a significant contributor to functional level ( $\beta = 0.39$ ,  $p <$   
29  $0.001$ ), explaining 15% of the variance.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41 **B. Core clinical symptom dimensions.** Only three clinical dimensions [depression and anxiety ( $\beta =$   
42  $-0.18$ ,  $p < 0.001$ ), positive symptoms ( $\beta = -0.17$ ,  $p < 0.001$ ), and negative symptoms ( $\beta = -0.26$ ,  
43  $p < 0.001$ )] were associated with functioning, whereas mania and disorientation were not  
44 significantly associated ( $p$ 's  $> 0.05$ ). The model demonstrated excellent fit ( $\chi^2 = 8.6$ ,  $df = 8$ ,  $p <$   
45  $0.379$ ,  $CFI = 0.999$ ,  $NFI = 0.986$ ,  $RMSEA = 0.009$ ,  $90\% CI = 0.000-0.043$ ), with the three  
46 dimensions explaining a total of 18% of the variance in functioning (see Figure 1B).  
47  
48  
49  
50  
51  
52  
53  
54 **C. Alcohol and substance use.** Exploratory factor analyses determined that alcohol use did not  
55 load with the other substance use variables. Only a two-factor latent model was possible given  
56  
57  
58  
59  
60

1 the number of observed variables and statistical constraints. The two-factor model emerged as  
2 an excellent fit for the data ( $\chi^2 = 7.4$ ,  $df = 4$ ,  $p < 0.116$ ,  $CFI = 0.995$ ,  $NFI = 0.990$ ,  $RMSEA =$   
3  $0.033$ ,  $90\% CI = 0.000-0.069$ ), whereby tobacco, cannabis and other illicit substance use  
4 loaded on a single 'substance use' latent variable as distinct from alcohol use (Figure 1C and  
5 legend). Only substance use was predictive of functioning ( $\beta = -0.10$ ,  $p < 0.05$ ), explaining 1%  
6 of the variance.  
7  
8  
9  
10  
11  
12  
13

14 [Insert Figure 1 about here]  
15  
16  
17  
18  
19

## 20 Final Model

21 In the overall model, all the factors identified in the single predictor models remained significant,  
22 except for substance use (Figure 2). Neurocognition showed the strongest unique contribution to  
23 social and occupational functioning ( $\beta = 0.36$ ,  $p < 0.001$ ); depressive symptoms were next ( $\beta = -$   
24  $0.24$ ,  $p < 0.001$ ), followed by negative symptoms ( $\beta = -0.15$ ,  $p < 0.001$ ) and finally positive  
25 symptoms ( $\beta = -0.10$ ,  $p < 0.001$ ). Together, these four clinical features independently accounted for  
26 31% of the variance in functioning, with the final model being a very good fit for the data ( $\chi^2 =$   
27  $279.8$ ,  $df = 119$ ,  $p < 0.000$ ,  $CFI = 0.956$ ,  $NFI = 0.926$ ,  $RMSEA = 0.037$ ,  $90\% CI = 0.031-0.042$ ).  
28 Mania, disorientation, and alcohol and substance use, all significantly correlated with these four  
29 significant features ( $p$ 's  $< 0.05$ ).  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42

43 [Insert Figure 2 about here]  
44  
45  
46  
47

## 48 Moderator Analyses

- 49 • *Age*. As shown in Table 3, positive symptoms were no longer a significant contributor to  
50 functioning in the 12- to 20-year-old group ( $\beta = -0.06$ ,  $p = 0.178$ ). The model with older  
51 individuals explained 18% more variance in functional impairment than the model with  
52 younger individuals. This was driven in large part by a difference in predictive strength of  
53  
54  
55  
56  
57  
58  
59



1 neurocognition, whereby it was more predictive in older ( $\beta = 0.44, p < 0.001$ ) than younger  
2 individuals ( $\beta = 0.27, p < 0.001$ ).  
3  
4

- 5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16
- *Gender.* Positive symptoms were non-significant in the male sub-group ( $\beta = -0.07, p = 0.145$ ), whereas all other clinical features remained significant ( $p$ 's  $< 0.001$ ). In females, negative symptoms became non-significant ( $\beta = -0.07, p = 0.105$ ), whilst the other contributors remained significant. The final model was comparable across genders in terms of the total variance explained.

17  
18 [Insert Table 2 about here]

- 19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44
- *Primary affective disorder diagnosis.* Neurocognition, depression and anxiety, and negative symptoms remained significant contributors to functional level irrespective of affective disorder diagnosis (see Table 4). By contrast, positive symptoms no longer remained significant in both the affective disorder ( $\beta = -0.63, p = 0.097$ ) and psychosis, developmental or behavioral disorders ( $\beta = -0.102, p = 0.123$ ) sub-groups. An additional 14% of the variance in functioning was explained in individuals with a psychotic, developmental or behavioral disorder, primarily owing to the greater predictive strength of neurocognition (0.30 vs. 0.43,  $p$ 's  $< 0.001$ ).
  - *Medication usage.* All factors associated with functional impairment remained significant in participants who were unmedicated. By contrast, positive symptoms no longer remained significant in medicated individuals ( $\beta = -0.06, p = 0.117$ ).

45 [Insert Table 3 about here]

## 50 Sensitivity Analysis

51  
52  
53 Restricting the full sample to individuals aged 15-25 years of age ( $N = 794$ ) yielded a very good  
54 fitting model as well ( $\chi^2 = 240.1, df = 119, p < 0.000, CFI = 0.959, NFI = 0.924, RMSEA = 0.036,$   
55  
56  
57  
58  
59  
90% CI = 0.029–0.042). The explained variance remained the same (31% explained). Importantly,

1 all predictors remained significant with the same effect sizes, with the exception of depression and  
2 anxiety, which became slightly more predictive (-0.25 → -0.26), and neurocognition, which became  
3 slightly less predictive (0.36 → 0.35).  
4  
5  
6  
7

## 8 **DISCUSSION**

9

10 In a large, clinical, transdiagnostic cohort of youth with mental disorders, impaired neurocognition  
11 was the clinical feature most significantly associated with functional impairment. The role of  
12 neurocognition was attenuated in those with an affective disorder diagnosis and in the younger age  
13 group. The findings are relevant as they demonstrate that whilst neurocognitive impairment may  
14 undermine functioning in those with psychotic disorders, or in chronic or recurrent mental  
15 disorders, they are not specific to such cases. That is, neurocognitive dysfunction has traditionally  
16 been argued as a core, underlying feature of social and occupational impairments in chronic  
17 schizophrenia. However, our current findings support the burgeoning position that the role of  
18 neurocognitive deficits cut across diagnosis and clinical stage. Nevertheless, it appears that  
19 neurocognitive disturbances are more pronounced in those with psychotic, developmental, or  
20 behavioural disorders, converging with evidence of more pronounced cognitive deficits in children  
21 who will go on to develop psychosis compared with those who develop depression or bipolar  
22 disorder<sup>48-50</sup>. Mechanistically, whether neurocognitive dysfunction drives functional impairment as  
23 a few past studies have found<sup>7,28</sup>, and is a consequence of poor functioning remains to be clarified.  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

42 Depressive, anxiety and negative symptom dimensions also contributed significantly to level  
43 of social and occupational functioning, supporting previous disorder-specific research.<sup>11 13 28</sup>  
44 Importantly, the contributions of these factors to level of functioning were largely independent of  
45 one another, and do not appear to be moderated by other clinical or demographic factors. By  
46 comparison, the role of positive symptoms diminished considerably in the final model. This finding  
47 differs from other research in psychotic and bipolar disorders, and may reflect the lower prevalence  
48 of positive symptoms in our cohort in contrast to previous studies.<sup>11 13 28</sup> However, it was notable  
49 that positive symptoms in older, unmedicated females remained significantly associated with  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 functioning. As with neurocognition however, the directionality of findings remains unclear, with  
2 some evidence suggesting that it may be bidirectional in the case of negative symptoms<sup>7 28 51</sup>.  
3  
4

5  
6 Intriguingly, neither alcohol and substance use, nor sleep disturbances, were directly  
7 associated with functional impairment, although these factors remained significantly associated  
8 with neurocognition and clinical symptoms. Therefore, their role in social and occupational  
9 functioning does not appear to be direct, but may operate indirectly (e.g., substance use may impair  
10 cognition, which in turn may impair functioning). The indirect effects of alcohol and substance use,  
11 as well as sleep and circadian disruptions, warrant more detailed examination and causal analysis in  
12 longitudinal datasets. Moreover, the lack of a direct association between alcohol and substance use  
13 and functioning may be related to the domains of neurocognitive functions currently tested. That is,  
14 the impact of substance use on functioning may be greatest in other neurocognitive functions that  
15 are more directly linked to driving and maintaining alcohol and substance use behaviours, such as  
16 those subserved by the fear, reward and self-control circuitries not covered in the current  
17 neuropsychological battery (e.g., reward-related cue learning, habit formation, response inhibition).  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31

32  
33 The current findings have important implications for the transdiagnostic, dimensional  
34 approach to psychiatry. Research examining the underlying mechanisms of functional impairment  
35 in single- or dual-diagnosis cohorts have been unable to capture the unique contributions of a  
36 comprehensive range of neurocognitive, symptom, sleep and circadian factors, as well as other  
37 psychoactive exposures (i.e., substance use, prescribed medications).<sup>22</sup> In particular,  
38 neuropsychological studies in psychosis have not routinely and concurrently assessed depression  
39 and anxiety symptoms, hypomania and full-threshold mania, substance misuse, and sleep  
40 disturbance. That is not to say that categorical, nosological approaches have had little to contribute  
41 to the field. Indeed, the key argument underpinning a DSM-approach is to allow for comparability  
42 across studies and so diagnostic determinations are often necessary. However, in youth, diagnoses  
43 tend to be unstable<sup>1</sup> and, as such, not as useful. One plausible way forward for dimensional  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 psychiatry is to ensure that the samples used in transdiagnostic studies are characterised as clearly  
2 and as comprehensively as possible,<sup>16 52 53</sup> as was attempted in the present investigation.  
3  
4  
5

6 In terms of limitations, the current analyses were cross-sectional, and future research  
7 investigating moderator and mediator analyses would benefit from cross-lagged, longitudinal path  
8 modelling to disentangle causality.<sup>54</sup> Secondly, the measures used to index clinical symptoms, sleep  
9 disturbance, and alcohol and substance use were not as comprehensive as is typical in the sleep and  
10 addiction literatures, and some were not originally designed for use in certain clinical disorders,  
11 which may have reduced sensitivity to detect symptoms (e.g., mania). More detailed examination of  
12 these dimensions in the future will help more definitively determine whether the impact of  
13 neurocognition on functioning is as large as currently identified. Future studies would also benefit  
14 from using real-time, ecological momentary assessment technologies (e.g., substance use  
15 monitoring using smartphones, actigraphy monitoring of physical activity and sleep quality).  
16 Thirdly, medication data were not available for the full sample (12.6% were missing) and, as such,  
17 the moderating role of medication status requires further corroboration (as with the role of  
18 medication type). Fourthly, clinical diagnoses assigned to cases in the current study were by  
19 treating psychiatrists and future studies should consider more structured approaches (e.g.,  
20 Structured Clinical Interview for DSM), including consideration of the influence of other comorbid  
21 diagnoses (e.g., personality disorders). Further, the age range included in the current study meant  
22 that individuals on the opposite ends of the age spectrum were at different stages of their cognitive  
23 and emotional development (e.g., executive functioning, emotional regulation), although our  
24 sensitivity analyses supports the argument that our findings hold irrespective of age. Finally, a  
25 phenotype-approach, as attempted in the current study, would necessarily require converging  
26 genetic and neuroimaging evidence to ensure that the neurocognitive and symptom dimensions  
27 identified as predictive of functioning are linked to specific neural circuitries (e.g., cortico-basal  
28 ganglia systems<sup>55</sup>) and genotype, which would ultimately facilitate the development of next-  
29 generation and neuroscience-informed pharmacotherapies.  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

This was the first study to examine a broad range of illness-related factors and associations with functional impairment in a well-powered and broadly transdiagnostic, clinical cohort of more than one thousand young people with mental illness. A significant contribution of the present findings to the established literature was evidence showing that neurocognition is a strong and reliable, unique predictor of social and occupational functioning irrespective of diagnosis – in a cohort predominantly comprised of affective disorders, which has not been previously demonstrated before at this scale. As such, the functional importance of neurocognitive functions clearly extends beyond the psychosis and developmental disorders spectrum and appears to become more pronounced with increasing age. Future studies should attempt to replicate these findings, as well as to clarify the directions of cause and effect.

## **AUTHORSHIP**

RSCL, DFH, SLN, AJG, NG, JS, EMS and IBH contributed to the conception of the study; RSCL, DFH, MK undertook the data collection, processing and analysis; RSCL wrote the first draft of the manuscript. All authors contributed to data interpretation, discussion and have approved the final manuscript.

## **FUNDING**

This study was supported by grants from the National Health & Medical Research Council (NHMRC) including: Centre of Research Excellence (No. 1061043), NHMRC Fellowship (No. 1046899) and Clinical Research Fellowship (No. 402864). The funders had no input to the study design, data collection, or interpretation, writing of report, or submission for publication.

## **COMPETING INTERESTS**

(1) No authors have support from any company for the submitted work; (2) no authors have relationships with any company that might have an interest in the submitted work; (3) no author, their spouses, partners, or children have financial relationships that may be relevant to the submitted work and; (4) no authors have any non-financial interests that may be relevant to the submitted work.

## **ETHICAL APPROVAL**

This study was approved by the University of Sydney Human Research Ethics Committee (reference 12130; protocol no. 2012/1631).

## **AVAILABILITY OF DATA AND MATERIALS**

The datasets generated and/or analysed during the current study are not publicly available due to the breadth and sensitivity of data collected, which may have implications for individual privacy, but are available from the corresponding author on reasonable request.

**REFERENCES**

1. Bromet EJ, Kotov R, Fochtmann LJ, et al. Diagnostic shifts during the decade following first admission for psychosis. *American Journal of Psychiatry* 2011;168(11):1186-94. doi: 10.1176/appi.ajp.2011.11010048 [published Online First: 2011/06/17]
2. Hickie IB, Scott J, Hermens DF, et al. Clinical classification in mental health at the cross-roads: which direction next? *BMC medicine* 2013;11:125. doi: 10.1186/1741-7015-11-125 [published Online First: 2013/05/16]
3. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. *Australian and New Zealand Journal of Psychiatry* 2006;40(8):616-22.
4. Cross SPM, Hermens DF, Scott EM, et al. A Clinical Staging Model for Early Intervention Youth Mental Health Services. *Psychiatric Services* 2014;65(7):939-43. doi: 10.1176/appi.ps.201300221
5. Lee RSC, Redoblado MA, Naismith SL, et al. Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. *Psychological Medicine* 2013;43(6):1161-73.
6. Cross SPM, Scott J, Hickie IB. Predicting early transition from sub-syndromal presentations to major mental disorders. *BJPsych Open* 2017;3(5):223-27. doi: 10.1192/bjpo.bp.117.004721
7. Lee RSC, Hermens D, Scott J, et al. A Transdiagnostic Study of Education, Employment, and Training Outcomes in Young People with Mental Illness. *Psychological Medicine* 2017;47:2061-70.
8. O'Dea B, Lee RS, McGorry PD, et al. A prospective cohort study of depression course, functional disability, and NEET status in help-seeking young adults. *Soc Psychiatry Psychiatr Epidemiol* 2016 doi: 10.1007/s00127-016-1272-x [published Online First: 2016/08/09]
9. Davidson L, O'Connell MJ, Tondora J, et al. Recovery in Serious Mental Illness: A New Wine or Just a New Bottle? *Professional Psychology: Research and Practice* 2005;36(5):480-87. doi: 10.1037/0735-7028.36.5.480
10. World Health Organization. Mental Health Action Plan 2013-2020. Geneva, Switzerland: World Health Organization 2013.
11. Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: A comparison of schizophrenia and bipolar disorder. *The American Journal of Psychiatry* 2010;167(9):1116-24.

12. Lee RSC, Hermens DF, Redoblado MA, et al. Neuropsychological and socio-occupational functioning in young psychiatric outpatients: a longitudinal investigation. *PLOS ONE* 2013;8(3):e58176. doi: 10.1371/journal.pone.0058176
13. Galderisi S, Rossi A, Rocca P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2014;13(3):275-87. doi: 10.1002/wps.20167
14. Thomas ML, Green MF, Helleman G, et al. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. *JAMA psychiatry (Chicago, Ill)* 2017;74(1):37-46. doi: 10.1001/jamapsychiatry.2016.2980 [published Online First: 2016/12/08]
15. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *The Lancet* 2013 doi: [http://dx.doi.org/10.1016/S0140-6736\(13\)61611-6](http://dx.doi.org/10.1016/S0140-6736(13)61611-6)
16. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2014;13(1):28-35. doi: 10.1002/wps.20087
17. Robbins TW, Gillan CM, Smith DG, et al. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. *Trends in Cognitive Sciences* 2012;16(1):81-91. doi: 10.1016/j.tics.2011.11.009
18. Millan MJ, Agid Y, BrÅ¼ne M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nature Reviews Drug Discovery* 2012;11(2):141-68.
19. HÅgele C, Schlagenhaut F, Rapp M, et al. Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. *Psychopharmacology* 2015;232(2):331-41. doi: 10.1007/s00213-014-3662-7
20. Yee CM, Javitt DC, Miller GA. Replacing DSM Categorical Analyses With Dimensional Analyses in Psychiatry Research: The Research Domain Criteria Initiative. *JAMA psychiatry (Chicago, Ill)* 2015;72(12):1159-60. doi: 10.1001/jamapsychiatry.2015.1900 [published Online First: 2015/11/13]
21. Miller GA. Mistreating Psychology in the Decades of the Brain. *Perspectives on psychological science : a journal of the Association for Psychological Science* 2010;5(6):716-43. doi: 10.1177/1745691610388774 [published Online First: 2011/09/29]



- 1 22. Iorfino F, Hickie IB, Lee RSC, et al. The underlying neurobiology of key functional domains in  
2 young people with mood and anxiety disorders: a systematic review. *BMC Psychiatry*  
3 2016;16(1):1-38. doi: 10.1186/s12888-016-0852-3
- 4 23. Lee RSC, Hermens DF, Naismith SL, et al. Neuropsychological and functional outcomes in  
5 recent-onset major depression, bipolar disorder and schizophrenia-spectrum disorders: A  
6 longitudinal cohort study. *Translational Psychiatry* 2015;5:e555.
- 7 24. Hermens D, Naismith S, Lagopoulos J, et al. Neuropsychological profile according to the  
8 clinical stage of young persons presenting for mental health care. *BMC Psychology*  
9 2013;1(1):8.
- 10 25. Scott EM, Hermens DF, Glozier N, et al. Targeted primary care-based mental health services  
11 for young Australians. *Medical Journal of Australia* 2012;196:136-40.
- 12 26. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of  
13 social functioning. *American Journal of Psychiatry* 1992;149(9):1148-56.
- 14 27. Lee RSC, Hermens DF, Redoblado-Hodge MA, et al. Neuropsychological and socio-  
15 occupational functioning in young psychiatric outpatients: a longitudinal investigation. *PLoS*  
16 *One* 2013;8 doi: 10.1371/journal.pone.0058176
- 17 28. Green MF, Helleman G, Horan WP, et al. From perception to functional outcome in  
18 schizophrenia: modeling the role of ability and motivation. *Archives of General Psychiatry*  
19 2012;69(12):1216-24. doi: 10.1001/archgenpsychiatry.2012.652 [published Online First:  
20 2012/10/03]
- 21 29. Strauss E, Sherman EMS, Spreen O. A Compendium of neuropsychological tests:  
22 Administration, norms, and commentary. 3rd ed. New York: Oxford University Press 2006.
- 23 30. Lezak MD, Howieson DB, Bigler ED, et al. Neuropsychological Assessment. 5th ed. ed. New  
24 York: Oxford University Press 2012.
- 25 31. Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale - Expanded  
26 (BPRS-E) structure and arguments for a new version. *Journal of Psychiatric Research*  
27 2016;81:140-51. doi: 10.1016/j.jpsychires.2016.07.001
- 28 32. Londborg PD, Smith WT, Glaudin V, et al. Short-term cotherapy with clonazepam and  
29 fluoxetine: anxiety, sleep disturbance and core symptoms of depression. *Journal of Affective*  
30 *Disorders* 2000;61(1-2):73-79. doi: [https://doi.org/10.1016/S0165-0327\(99\)00195-0](https://doi.org/10.1016/S0165-0327(99)00195-0)
- 31 33. Hamilton M. A rating scale for depression. *Journal of Neurology, Neurosurgery & Psychiatry*  
32 1960;23(1):56-62.
- 33 34. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders  
34 Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with

- 1 Harmful Alcohol Consumption--II. *Addiction (Abingdon, England)* 1993;88(6):791-804.  
2 [published Online First: 1993/06/01]  
3  
4  
5 35. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening  
6 Test (ASSIST): Development, reliability and feasibility. *Addiction (Abingdon, England)*  
7 2002;97(9):1183-94. [published Online First: 2002/08/30]  
8  
9  
10 36. Arbuckle JL. IBM SPSS Amos 20 User's Guide: IBM Corporation 2011.  
11  
12 37. Miot HA. Avaliação da normalidade dos dados em estudos clínicos e experimentais. *Jornal*  
13 *Vascular Brasileiro* 2017;16:88-91.  
14  
15 38. Bentler PM. Comparative Fit Indexes in Structural Models. *Psychological Bulletin*  
16 1990;107(2):238-46.  
17  
18 39. Bentler PM, Bonett DG. Significance tests and goodness of fit in the analysis of covariance  
19 structures. *Psychological Bulletin* 1980;88(3):588-606.  
20  
21 40. Steiger JH. Tests for comparing elements of a correlation matrix. *Psychological Bulletin*  
22 1980;87(2):245-51.  
23  
24 41. Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation  
25 models: Tests of significance and descriptive goodness-of-fit measures. *Methods of*  
26 *Psychological Research-Online* 2003;8:23-74. doi: citeulike-article-id:7222182  
27  
28 42. Jöreskog K, Sörbom D. LISREL 8: Structural Equation Modeling with the SIMPLIS Command  
29 Language Chicago, IL: Scientific Software International Inc. 1993.  
30  
31 43. Wheaton B, Muthen B, Alwin D, et al. Assessing Reliability and Stability in Panel Models.  
32 *Sociological Methodology* 1977;8:84-136.  
33  
34 44. Tabachnick B, Fidell L. Using Multivariate Statistics (5th ed.). New York: Allyn and Bacon  
35 2007.  
36  
37 45. Kline R. Principles and Practice of Structural Equation Modeling (2nd ed.) New York: The  
38 Guilford Press 2005.  
39  
40 46. Lee RSC, Hermens DF, Porter MA, et al. A meta-analysis of cognitive deficits in first-episode  
41 Major Depressive Disorder. *Journal of Affective Disorders* 2012;140(2):113-24. doi:  
42 10.1016/j.jad.2011.10.023  
43  
44 47. Lee RSC, Hermens DF, Scott J, et al. A meta-analysis of neuropsychological functioning in  
45 first-episode bipolar disorders. *Journal of Psychiatric Research* 2014;57:1-11. doi:  
46 10.1016/j.jpsychires.2014.06.019  
47  
48 48. Reichenberg A, Weiser M, Rabinowitz J, et al. A population-based cohort study of premorbid  
49 intellectual, language, and behavioral functioning in patients with schizophrenia,  
50 schizoaffective disorder, and nonpsychotic bipolar disorder. *Am J Psychiatry*  
51 2002;159(12):2027-35. [published Online First: 2002/11/27]  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
49. Koenen KC, Moffitt TE, Roberts AL, et al. Childhood IQ and adult mental disorders: a test of the cognitive reserve hypothesis. *Am J Psychiatry* 2009;166(1):50-7. doi: 10.1176/appi.ajp.2008.08030343 [published Online First: 2008/12/03]
50. Zammit S, Allebeck P, David AS, et al. A longitudinal study of premorbid IQ score and risk of developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses. *Archives of General Psychiatry* 2004;61(4):354-60. doi: 10.1001/archpsyc.61.4.354
51. Nakagami E, Hoe M, Brekke JS. The Prospective Relationships Among Intrinsic Motivation, Neurocognition, and Psychosocial Functioning in Schizophrenia. *Schizophrenia Bulletin* 2010;36(5):935-48. doi: 10.1093/schbul/sbq043
52. Casey BJ, Craddock N, Cuthbert BN, et al. DSM-5 and RDoC: progress in psychiatry research? *Nature reviews Neuroscience* 2013;14(11):810-14. doi: 10.1038/nrn3621
53. Craddock N, Owen MJ. Rethinking psychosis: the disadvantages of a dichotomous classification now outweigh the advantages. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2007;6(2):84-91. [published Online First: 2008/02/01]
54. Breitborde NJ, Srihari VH, Pollard JM, et al. Mediators and moderators in early intervention research. *Early Interv Psychiatry* 2010;4(2):143-52. doi: 10.1111/j.1751-7893.2010.00177.x [published Online First: 2010/06/12]
55. Griffiths KR, Lagopoulos J, Hermens DF, et al. Impaired causal awareness and associated cortical–basal ganglia structural changes in youth psychiatric disorders. *NeuroImage: Clinical* 2016;12:285-92. doi: <http://dx.doi.org/10.1016/j.nicl.2016.06.017>

**Table 1** Demographic, clinical and functional characteristics across diagnostic sub-groups

	DEPRESSION <sup>1</sup> (n = 449)		BIPOLAR <sup>2</sup> (n = 178)		PSYCHOSIS <sup>3</sup> (n = 193)		ANXIETY <sup>4</sup> (n = 109)		DEV/BEHAV <sup>5</sup> (n = 74)	
	M	SD	M	SD	M	SD	M	SD	M	SD
Age	19.8	4.3	21.6	4.8	22.2	4.6	19.9	4.8	17.0	4.6
Education (years)	11.6	2.4	12.3	2.2	12.0	2.4	11.5	2.7	10.0	2.8
BPRS Depression (/7)	2.4	0.8	2.2	0.8	2.1	0.9	2.3	0.9	1.7	0.7
BPRS Mania (/7)	1.3	0.5	1.5	0.6	1.4	0.4	1.4	0.4	1.5	0.7
BPRS Positive (/7)	1.3	0.4	1.4	0.5	1.8	0.7	1.4	0.5	1.3	0.4
BPRS Negative (/7)	1.5	0.6	1.3	0.5	1.9	0.8	1.5	0.7	1.5	0.6
BRPS Disorientation (/7)	1.2	0.5	1.1	0.5	1.2	0.6	1.2	0.5	1.2	0.5
HDRS Sleep (/6)	2.0	1.8	1.7	1.7	1.3	1.6	1.5	1.5	1.8	1.7
AUDIT Alcohol Use (/40)	6.8	7.4	9.0	8.4	6.2	8.0	4.4	6.4	5.1	7.5
WHO-ASSIST Tobacco Use (/4)	1.3	1.6	1.6	1.7	1.7	1.9	1.0	1.5	1.4	1.7
WHO-ASSIST Cannabis Use (/4)	0.7	1.2	0.7	1.3	0.4	1.0	0.4	0.9	0.7	1.3
WHO-ASSIST Other Illicit Substance Use (/4)	0.1	0.3	0.1	0.3	0.1	0.2	0.1	0.3	0.1	0.3
SOFAS	61.8	10.7	63.9	11.5	55.9	12.1	63.2	11.1	61.7	9.8
	N	%	N	%	N	%	N	%	N	%
Gender (female)	277	61.7	129	72.5	58	30.1	58	53.2	20	27.0
Medicated <sup>†</sup>	231	60.0	128	77.6	140	77.3	37	45.7	32	49.2
Antidepressants	201	52.2	63	38.2	55	30.4	25	30.9	12	18.5
Lithium/Anticonvulsants	28	7.3	69	41.8	24	13.3	6	7.4	3	4.6
Antipsychotics	71	18.4	77	46.7	125	69.1	9	11.1	8	12.3
Stimulants	14	3.6	7	4.2	3	1.7	4	4.9	14	21.5

AUDIT–Alcohol Use Disorders Identification Test; BPRS–Brief Psychiatric Rating Scale; DEV/BEHAV–Developmental/Behavioral; HDRS–Hamilton Depression Rating Scale; SOFAS–Social and Occupational Functioning Assessment Scale; WHO-ASSIST–World Health Organization – Alcohol, Smoking and Substance Involvement Screening Test

<sup>1</sup> Major Depressive Disorder (n=313), Dysthymic Disorder (n=4), Depressive Disorder Not Otherwise Specified (n=132)

<sup>2</sup> Bipolar I Disorder (n=13), Bipolar II Disorder (n=25), Cyclothymic Disorder (n=1), Bipolar Disorder Not Otherwise Specified (n=139)

<sup>3</sup> Schizophrenia (n=53), Schizophreniform Disorder (n=15), Schizoaffective Disorder (n=26), Brief Psychotic Disorder (n=11), Substance-Induced Psychotic Disorder (n=14), Psychotic Disorder Not Otherwise Specified (n=74)

<sup>4</sup> Panic Disorder (n=4), Social Phobia (n=29), Obsessive-Compulsive Disorder (n=11), Posttraumatic Stress Disorder (n=5), Generalised Anxiety Disorder (n=60)

<sup>5</sup> Asperger's Disorder (n=16), Attention-Deficit/Hyperactivity Disorder (n=47), Conduct Disorder (n=7), Oppositional Defiant Disorder (n=4)

<sup>†</sup> Medication data was available in 877 individuals (87.4%), with missing data for the typologies of Depression (n=64), Bipolar (n=13), Psychosis (n=12), Anxiety (n=28), Developmental (n=9)

**Table 2** Neuropsychological functioning across diagnostic sub-groups

	DEPRESSION (n = 449)		BIPOLAR (n = 178)		PSYCHOSIS (n = 193)		ANXIETY (n = 109)		DEV/BEHAV (n = 74)	
	M	SD	M	SD	M	SD	M	SD	M	SD
IQ <sup>1</sup>	<b>103.25</b>	10.49	<b>102.82</b>	9.08	<b>99.99</b>	10.47	<b>102.66</b>	9.59	<b>95.30</b>	14.83
Trails A <sup>2</sup>	<b>-0.01</b>	1.32	<b>0.16</b>	1.06	<b>-0.31</b>	1.01	<b>0.12</b>	0.96	<b>-0.03</b>	1.07
Trails B <sup>2</sup>	<b>-0.44</b>	1.53	<b>-0.47</b>	1.92	<b>-1.22</b>	2.23	<b>-0.50</b>	1.59	<b>-0.85</b>	2.16
Rey Total <sup>2</sup>	<b>-0.06</b>	1.27	<b>-0.18</b>	1.20	<b>-1.12</b>	1.46	<b>0.09</b>	1.93	<b>-0.48</b>	1.42
Rey Delay <sup>2</sup>	<b>0.03</b>	1.34	<b>-0.27</b>	1.38	<b>-1.07</b>	1.51	<b>0.18</b>	2.29	<b>-0.29</b>	1.22
FAS <sup>2</sup>	<b>-0.31</b>	1.15	<b>-0.04</b>	1.07	<b>-0.56</b>	1.00	<b>-0.37</b>	1.15	<b>-0.86</b>	1.09
Animals <sup>2</sup>	<b>0.23</b>	1.20	<b>0.45</b>	1.25	<b>-0.28</b>	1.08	<b>0.26</b>	1.17	<b>-0.03</b>	0.94

<sup>1</sup> Age-adjusted; normative M = 100; SD = 15.

<sup>2</sup> Demographically-adjusted; normative M= 0.00; SD = 1.00.

**Table 3** Analyses of demographic factors (age, gender) as moderators of the relationships between predictors and functional outcome in the final model

	Age <sup>†</sup>				Gender <sup>‡</sup>			
	12-20 Years (n = 539)		21-36 Years (n = 464)		Male (n = 461)		Female (n = 542)	
	$\beta$	p-value	$\beta$	p-value	$\beta$	p-value	$\beta$	p-value
Neurocognition	.27	.000	.44	.000	.35	.000	.35	.000
Depression and Anxiety	-.28	.000	-.22	.000	-.23	.000	-.30	.000
Positive Symptoms	-.06	.178	-.14	.002	-.07	.145	-.12	.004
Negative Symptoms	-.13	.005	-.18	.000	-.19	.000	-.07	.105

<sup>†</sup> 12-20 Years (Subgroup Model,  $R^2=.24$ ); 21-36 Years (Subgroup Model,  $R^2=.40$ )

<sup>‡</sup> Male (Subgroup Model,  $R^2=.32$ ); Female (Subgroup Model,  $R^2=.29$ )

**Table 4** Analyses of clinical factors (primary affective disorder, medication usage) moderating the relationship between predictors and functional outcome in the final model

	Primary Affective Disorder <sup>†</sup>				Medication Usage <sup>‡</sup>			
	Yes (n = 736)		No (n = 267)		Nil (n = 309)		Medicated (n = 568)	
	$\beta$	p-value	$\beta$	p-value	$\beta$	p-value	$\beta$	p-value
Neurocognition	.30	.000	.43	.000	.38	.000	.38	.000
Depression and Anxiety	-.29	.000	-.24	.000	-.15	.007	-.24	.000
Positive Symptoms	-.06	.097	-.10	.123	-.22	.000	-.06	.117
Negative Symptoms	-.12	.003	-.16	.009	-.19	.000	-.13	.002

<sup>†</sup> Yes (Subgroup Model,  $R^2=.24$ ); No (Subgroup Model,  $R^2=.38$ )

<sup>‡</sup> Nil (Subgroup Model,  $R^2=.38$ ); Medicated (Subgroup Model,  $R^2=.29$ )

**Figure 1** Combined measurement and structural models for functioning and (A) neurocognition, (B) core clinical symptoms, and (C) alcohol and substance use.

*Legend:*

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except path between substance use and functional outcome; where  $p < .05$ )

Factor Loadings for (A) Neurocognition (all  $p$ 's  $< .001$ ): IQ (.58), Trails A (-.51), Trails B (-.55), Rey Total (.69), Rey Delay (.59), FAS (.57), Animals (.51)

Factor Loadings for (C) Substance Use (all  $p$ 's  $< .001$ ): Tobacco (.81), Cannabis (.64), Other (.68)

**Figure 2** Final model.

*Legend:*

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except correlation between substance use and positive symptoms, where  $p < .05$ ). Where no path is drawn it denotes no significant relationship between the variables (see Figure 1 for all factor loadings of latent variables).






Figure 1 Combined measurement and structural models for functioning and (A) neurocognition, (B) core clinical symptoms, and (C) alcohol and substance use.

Legend:

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except path between substance use and functional outcome; where  $p < .05$ )

Factor Loadings for (A) Neurocognition (all  $p$ 's  $< .001$ ): IQ (.58), Trails A (-.51), Trails B (-.55), Rey Total (.69), Rey Delay (.59), FAS (.57), Animals (.51)

Factor Loadings for (C) Substance Use (all  $p$ 's  $< .001$ ): Tobacco (.81), Cannabis (.64), Other (.68)

230x199mm (300 x 300 DPI)




Figure 2 Final model.

## Legend:

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except correlation between substance use and positive symptoms, where  $p < .05$ ). Where no path is drawn it denotes no significant relationship between the variables (see Figure 1 for all factor loadings of latent variables).

393x208mm (300 x 300 DPI)

**STROBE Statement**—checklist of items that should be included in reports of observational studies

RE: “*A cross-sectional study of clinical, neurocognitive, and demographic factors associated with functional impairment in the Brain and Mind Youth Cohort*”

	Item No	Recommendation	Authors Response
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract <b>Pg. 1</b>	Yes
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found <b>Pg. 2</b>	Yes
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <b>Pg. 4-6</b>	Yes
Objectives	3	State specific objectives, including any prespecified hypotheses <b>Pg. 6</b>	Yes
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper <b>Pg. 6-7</b>	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <b>Pg. 7</b>	Yes
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants <b>Pg. 7</b>	Yes
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <b>Pg. 7-11</b>	Yes
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <b>Pg. 8</b>	Yes
Bias	9	Describe any efforts to address potential sources of bias <b>Pg. 10-11</b>	Yes
Study size	10	Explain how the study size was arrived at <b>Pg. 10</b>	Yes
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <b>Pg. 9-11</b>	Yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <b>Pg. 9-11</b>	Yes
		(b) Describe any methods used to examine subgroups and interactions <b>Pg. 10-11</b>	Yes
		(c) Explain how missing data were addressed <b>Pg. 9</b>	Yes
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls	NA

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

was addressed

~~Cross-sectional study~~—If applicable, describe analytical methods taking account of sampling strategy

---

(e) Describe any sensitivity analyses

NA

Continued on next page

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2018-022659 on 18 December 2018. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

Results			Authors Response
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <a href="#">Pg. 11</a>	Yes
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <a href="#">Pg. 11</a>	Yes
		(b) Indicate number of participants with missing data for each variable of interest <a href="#">Pg. 9</a>	Yes
		© <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<del><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</del>	Yes
		<del><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</del>	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures <a href="#">Pg. 11</a>	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <a href="#">Pg. 12-13</a>	Yes
		(b) Report category boundaries when continuous variables were categorized <a href="#">Pg. 10-11</a>	Yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses <a href="#">Pg. 11-14</a>	Yes
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives <a href="#">Pg. 14-15</a>	Yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <a href="#">Pg. 15-16</a>	Yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <a href="#">Pg. 14-16</a>	Yes
Generalisability	21	Discuss the generalisability (external validity) of the study results <a href="#">Pg. 16</a>	Yes
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <a href="#">Pg. 17</a>	Yes

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at [www.strobe-statement.org](http://www.strobe-statement.org).

For peer review only

# BMJ Open

## Clinical, neurocognitive, and demographic factors associated with functional impairment in the Australian Brain and Mind Youth Cohort Study (2008-2016)

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-022659.R2
Article Type:	Research
Date Submitted by the Author:	17-Oct-2018
Complete List of Authors:	Lee, Rico; Monash University School of Psychological Sciences Hermens, Daniel; Brain & Mind Research Institute , Naismith, Sharon; Brain & Mind Research Institute, Kaur, Manreena; Monash Alfred Psychiatry Research Centre Guastella, Adam; Brain & Mind Research Institute, Clinical Research Unit Glozier, Nick; Brain & Mind Research Institute, Clinical Research Unit Scott, Jan; Newcastle University, Institute of Neuroscience Scott, Elizabeth; Brain & Mind Research Institute, Hickie, Ian; The University of Sydney, Brain and Mind Centre;
<b>Primary Subject Heading</b>:	Mental health
Secondary Subject Heading:	Mental health
Keywords:	neurocognition, transdiagnostic, functional impairment, mental illness, symptom dimensions, alcohol use

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7 **CLINICAL, NEUROCOGNITIVE, AND DEMOGRAPHIC FACTORS**  
8  
9 **ASSOCIATED WITH FUNCTIONAL IMPAIRMENT IN THE AUSTRALIAN**  
10  
11 **BRAIN AND MIND YOUTH COHORT STUDY (2008-2016)**  
12  
13  
14  
15  
16  
17

18 Rico S C Lee<sup>1,2</sup>, Daniel F Hermens<sup>3,4</sup>, Sharon L Naismith<sup>1,3</sup>, Manreena Kaur<sup>1,4</sup>, Adam J Guastella<sup>1</sup>,  
19  
20 Nick Glozier<sup>1,5</sup>, Jan Scott<sup>6,7</sup>, Elizabeth M Scott<sup>1</sup>, Ian B Hickie<sup>1</sup>  
21  
22  
23  
24  
25

26 <sup>1</sup> Brain and Mind Centre, University of Sydney, Australia  
27

28 <sup>2</sup> Brain and Mental Health Research Hub, Monash University, Australia  
29

30 <sup>3</sup> Charles Perkins Centre, University of Sydney, Australia  
31

32 <sup>4</sup> The Monash Alfred Psychiatry Research Centre, Monash University, Australia  
33

34 <sup>5</sup> Marie Bashir Institute, University of Sydney, Australia  
35

36 <sup>6</sup> Academic Psychiatry, Institute of Neuroscience, Newcastle University, UK  
37

38 <sup>7</sup> Centre for Affective Disorders, Institute of Psychiatry, Psychology and Neuroscience, UK  
39  
40  
41  
42  
43  
44  
45  
46  
47

48 Abstract word count: 243  
49

50 Manuscript word count: 4601  
51

52 Tables and figures: 4 tables, 2 figures  
53  
54  
55  
56  
57  
58  
59  
60



1  
2 <sup>ψ</sup> Corresponding author: Dr Rico S. C. Lee, Monash Biomedical Imaging, 770 Blackburn Rd, Clayton  
3  
4 VIC, 3800; Phone: +61 3 9902 9808; Email: rico.lee@monash.edu.  
5  
6

## 7 ABSTRACT

8  
9  
10 **Objectives:** We sought to determine the unique and shared contributions of clinical, neurocognitive and  
11  
12 demographic factors to functional impairment in a large, transdiagnostic, clinical cohort of  
13  
14 adolescents and young adults.  
15

16  
17 **Design:** Cross-sectional baseline data from a prospective, cohort study.  
18

19  
20 **Setting:** Help-seeking youth referred from outpatient services were recruited to the *Brain and Mind*  
21  
22 *Youth Cohort* (2008-2016) in Sydney, Australia.  
23

24  
25 **Participants:** In total, 1003 outpatients were recruited, aged between 12 and 36 years (M = 20.4 years,  
26  
27 54% female), with baseline diagnoses of affective, psychotic, developmental or behavioural  
28  
29 disorders.  
30

31  
32 **Interventions:** Treatment as usual.  
33

34  
35 **Primary outcome measures:** Social and occupational functioning was used to index level of functional  
36  
37 impairment. Structural equation modelling was used to examine associations between  
38  
39 neurocognition, core clinical symptoms, and alcohol and substance use, and clinician- and  
40  
41 researcher-rated functional impairment. Moderator analyses were conducted to determine the  
42  
43 potential influence of demographic and clinical factors (e.g. medication exposure).  
44  
45

46  
47 **Results:** Independent of diagnosis, we found that neurocognitive impairments, and depressive, anxiety  
48  
49 and negative symptoms, were significantly associated with functioning. The association of  
50  
51 neurocognition with social and occupational functioning remained significant even when  
52  
53 constraining age (only 15- to 25-year olds) or diagnosis (affective disorder) in the final model.  
54  
55  
56  
57  
58  
59

1  
2 **Conclusions:** This study demonstrates that, in a clinically representative sample of youth, the key  
3  
4 determinants of functioning may not be disorder specific. Further, evidence of neurocognitive  
5  
6 dysfunction suggests that interventions that target cognition and functioning should not  
7  
8 necessarily be reserved only for older adults with established illness.  
9

10  
11 **Keywords:** Neurocognition; transdiagnostic; functional impairment; mental illness; symptom  
12  
13 dimensions; alcohol use.  
14  
15

## 16 17 18 **STRENGTHS AND LIMITATIONS OF THIS STUDY**

- 19  
20 • This was one of the largest studies to date ( $N > 1,000$ ) to examine the associations between a  
21  
22 broad range of illness characteristics and functional impairment in a mostly adolescent and young  
23  
24 adult, clinical sample.  
25  
26
- 27 • Given the transdiagnostic approach, this study was equipped to disentangle the shared and unique  
28  
29 associations between core illness phenotypes and functional impairment across a range of  
30  
31 common mental disorders.  
32  
33
- 34 • The use of latent-variable, structural equation modelling controlled for aspects of measurement  
35  
36 imprecision.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## INTRODUCTION

In recent decades, early intervention services for youth with emerging mental disorders have extended their targets beyond those at risk of psychosis to also encompass those presenting with mood as well as other developmental and anxiety disorders. This approach creates several significant challenges. For example, some youth with depressive and anxiety disorders will ultimately develop psychotic or bipolar disorders; likewise, only a proportion of those receiving a diagnosis of bipolar disorders will consistently receive this diagnosis over the following 10 years.<sup>1</sup> The lack of diagnostic stability in help-seeking youth reflects the evolving disease process and means that the illness trajectory is less certain than for older adults with established illness.<sup>2 3</sup> From a research perspective, the use of dimensional approaches to phenomenology has helped us to understand illness progression in these early clinical stages, whilst from a clinical perspective, care and treatment have increasingly considered transdiagnostic interventions addressing core factors that may influence prognosis irrespective of cross-sectional diagnosis (e.g., anxiety, depressive or negative symptoms; sleep disturbances).<sup>4 5</sup> These approaches have highlighted that, in youth, a more meaningful measure of outcome may be functioning rather than change in diagnosis-specific symptoms. There is evidence to support this approach as level of functioning or disengagement (e.g., not being in education, employment or training, referred to as being NEET) is associated with early transition to major mental disorder<sup>6</sup> and with poor outcome of acute illness episodes.<sup>7 8</sup> However, to optimize interventions that target functioning it is important to understand the factors that contribute to level of functioning at clinical presentation. For instance, as well as transdiagnostic symptom dimensions, it is likely that other factors such as neurocognitive functioning and alcohol or substance use will also affect overall functioning. Disentangling the contribution and magnitude of any effects of these factors on functioning is important to determine which factors may be amenable to modification and allow clinicians to design a multidimensional intervention package.

1  
2 The proposal that social and occupational functioning should be a primary target for mental health  
3  
4 interventions is not new and is increasingly promoted for older adults with established illness. For  
5  
6 example, senior policy experts in the U.S. have stipulated that recovery-oriented treatments should form  
7  
8 the overarching goal of mental health care and the foundation of strategic health policy.<sup>9</sup> The recognition  
9  
10 that more personalized interventions are urgently needed to enhance functioning and quality of life rather  
11  
12 than simply targeting diagnosis-specific symptoms in a one-size-fits-all approach is also emphasized by  
13  
14 the World Health Organization.<sup>10</sup> Given this interest in enhancement of functioning across all stages of  
15  
16 mental illness and for youth and adults presenting to mental health services, it is therefore useful to  
17  
18 examine the role of other, key clinical (e.g., medication exposure) and demographic factors (e.g., age,  
19  
20 gender) in determining functioning, which would contribute to prognosis and attempts at personalised  
21  
22 medicine.  
23  
24  
25  
26  
27

28 Most path modelling studies to date have used small, single- or dual-diagnosis cohorts,  
29  
30 predominantly in individuals with a chronic mental illness. Findings consistently demonstrate that  
31  
32 neurocognition and negative symptoms are robust predictors of functional outcome in schizophrenia and  
33  
34 bipolar disorder.<sup>7 11 12</sup> By contrast, the impact of affective and positive symptoms on functioning remains  
35  
36 more equivocal. More recently, these findings have been replicated in large cohort studies,<sup>13 14</sup> although  
37  
38 the vast majority of existing studies have focused exclusively on schizophrenia. There have been no well-  
39  
40 powered studies examining a mental disorder other than schizophrenia, such as affective disorders,  
41  
42 despite depression being the leading cause of disability worldwide.<sup>15</sup> Studies have also largely  
43  
44 sidestepped the issue of psychotropic medication use. Furthermore, given that more than 75% of mental  
45  
46 illnesses emerge before the age of 25,<sup>3</sup> examining younger cohorts is critically important for the  
47  
48 development of novel approaches to early intervention since most studies to date have targeted older  
49  
50 individuals.<sup>15</sup>  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2 In order to build upon prior research, a transdiagnostic and dimensional approach is ideally  
3 positioned to disentangle the factors associated with functioning. Key to this research strategy is the  
4 examination of shared constructs (e.g., neurocognition) with clear links to pathophysiology,<sup>16-18</sup> which  
5 can inform novel therapeutics that target specific neural circuitries.<sup>17 19</sup> Transdiagnostic studies are also  
6 able to harness the variance across disorders, with the goal of developing robust, unifying models that  
7 are *explanatory* in nature.<sup>2</sup> Data showing that physiological and genetic risk factors for mental illness  
8 extend across, rather than are bound by, traditional diagnoses,<sup>20</sup> further supports this paradigm, as does  
9 the frequent prescription of psychotropic medications for off-label use across diagnostic boundaries.<sup>21</sup>  
10 Transdiagnostic studies are also superior to single-diagnosis case-control studies in that they can  
11 determine which relationships are *shared* across various diagnoses and which are *unique* to a particular  
12 disorder.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

28 In this study, we sought to determine whether: (i) neurocognition; (ii) core clinical dimensions;  
29 and (iii) alcohol and substance use, are associated with social and occupational functioning and the  
30 magnitude of these associations. The rationale for examining clinical symptoms and functioning  
31 alongside neurocognition, sleep changes, and substance use, is underscored by a recent systematic review  
32 highlighting the transdiagnostic relevance of these key domains in youth with mental illness.<sup>22</sup> In keeping  
33 with prior research,<sup>7 12 23</sup> it was hypothesized that neurocognition and negative symptoms would make  
34 the greatest contribution to level of social and occupational functioning irrespective of the cross-sectional  
35 diagnosis applied to cases at the time of inclusion in the cohort. Given the high degree of heterogeneity  
36 expected in a transdiagnostic youth sample, we secondarily sought to determine the influence of  
37 demographic (e.g., age, gender) and clinical factors (e.g., diagnosis, medication exposure) on findings.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

## 54 METHODS

55  
56  
57  
58  
59  
60

1  
2 This study was approved by the University of Sydney Human Research Ethics Committee. Data included  
3  
4 in the current study represent the baseline assessments conducted at entry to the cohort study, and were  
5  
6 collected between April 2008 and May 2016.  
7  
8  
9  
10

## 11 **Participants**

12  
13  
14  
15 Participants were recruited into the Brain and Mind Youth Cohort from youth mental health outpatient  
16  
17 services at the Brain and Mind Centre.<sup>24 25</sup> Referred participants were 12–36 years of age and presented  
18  
19 with a major affective, psychotic or developmental/behavioral syndrome. Participants were excluded if  
20  
21 they (or their guardians, if aged under 16 years) were unwilling or unable to provide written informed  
22  
23 consent, or if they had a pre-existing neurological condition, clinically assessed impaired English  
24  
25 language skills and/or intellectual disability that precluded completion of study self-ratings. Eligible  
26  
27 participants completed a series of observer and self-rated questionnaires.  
28  
29  
30  
31  
32  
33

## 34 **Procedure**

35  
36  
37 Treating clinicians recorded clinical diagnoses and these were reviewed at consensus meetings by senior,  
38  
39 treating psychiatrists (e.g., IBH, EMS) and formal diagnoses recorded based on the DSM-IV-TR (Table  
40  
41 1 provides details of diagnoses and sample characteristics). Any disagreements in diagnosis were  
42  
43 resolved at these consensus meetings with the relevant treating team. All participants received their  
44  
45 prescribed course of medications and interventions, as independently determined in consultation with  
46  
47 their treating clinicians.  
48  
49  
50

51  
52 Board-certified treating clinicians (i.e., consultant psychiatrists, clinical psychologists, mental  
53  
54 health nurses) provided an evaluation of each participant's social and occupational functioning. Next,  
55  
56 board-certified clinical psychologists, clinical neuropsychologists, or trained research psychologists (i.e.,  
57  
58  
59  
60

graduate-level academic psychologists; supervised by RSCL to ensure a sufficient level of inter-rater reliability), conducted structured clinical interviews, neuropsychological testing, as well as an additional assessment of social and occupational functioning to improve the reliability of this single, clinician-rated score (approximately 80% were conducted within a month of the treating clinician assessment).

## Measures

- *Social and occupational functioning* was indexed using the Social and Occupational Assessment Functioning Scale (SOFAS<sup>26</sup>). Scores were averaged across the treating clinician and researcher assessments (ICC = 0.70), as previously done.<sup>27</sup> This composite score was derived to obtain a more reliable estimate of real-world functioning and, secondarily, to conserve free parameters and increase stability of parameter estimates.<sup>23 28</sup> A higher score denotes better functioning.
- *Neurocognition* was assessed using a broad neuropsychological battery with demographic normative-adjustments (previously described<sup>23</sup>), and was chosen on the basis of sound psychometric properties<sup>29</sup> and relevance to the disorders under study.<sup>30</sup> Predicted IQ was estimated using the Wechsler Test of Adult Reading (WTAR) or Wide Range Achievement Test—fourth edition (WRAT-4, for participants younger than 16 years). Psychomotor speed and mental flexibility were measured using Trail Making Test—Part A (TMT-A) and -Part B (TMT-B). Verbal learning and memory were indexed using the five-trial total and delayed recall scores from the Rey Auditory Verbal Learning Test (RAVLT). Verbal fluency was comprised of the letter (FAS) and category (animals) fluency subtests of the Controlled Oral Word Association Test. A higher score indicates better functioning.
- *Core clinical symptom dimensions* were measured across two validated scales. Symptoms were rated on the expanded Brief Psychiatric Rating Scale (BPRS) using empirically-derived symptom sub-

1  
2 scores (depression and anxiety, mania, positive symptoms, negative symptoms, and  
3  
4 disorientation<sup>31</sup>). The BPRS does not capture sleep profiles as a separate dimension so, as in previous  
5  
6 studies,<sup>32</sup> disturbed sleep was indexed using the sum of the three sleep items from the Hamilton  
7  
8 Depression Rating Scale (HDRS<sup>33</sup>). A higher score denotes greater severity of symptoms.

- 9  
10  
11 • *Alcohol and substance use* were measured across two validated scales. Alcohol use was indexed  
12  
13 using the Alcohol Use Disorders Identification Test (AUDIT<sup>34</sup>) total score. Substance use for  
14  
15 tobacco, cannabis, and other illicit substances was measured using the ‘current frequency’ sub-scale  
16  
17 (past 3 months) from the World Health Organization – Alcohol, Smoking and Substance  
18  
19 Involvement Screening Test (WHO-ASSIST) questionnaire.<sup>35</sup> A higher score indicates greater  
20  
21 alcohol or substance use.  
22  
23  
24  
25  
26  
27  
28

### 29 **Patient and public involvement**

30  
31 Participants were not involved in the development of research question(s), design and outcome measures,  
32  
33 nor was the study informed by their priorities, experience, and preferences. We did not formally assess  
34  
35 the burden of time required to participate in the research.  
36  
37  
38  
39  
40  
41

### 42 **Data Analysis**

43  
44 Statistical analyses were conducted using IBM SPSS 20.0 and AMOS 20.0. Maximum likelihood  
45  
46 estimation (MLE) was employed for all structural equation modelling (SEM) analyses. MLE was chosen  
47  
48 as it is the most robust approach in the potential event of statistical assumption violations and performs  
49  
50 best in heterogeneous samples<sup>36</sup>. Missing data was also handled by MLE, which does not involve data  
51  
52 imputation, but uses all available data to compute maximum likelihood estimates. Diagnostic and  
53  
54 demographic data were available for all participants. In total, 9.1% of data were missing for functioning,  
55  
56  
57  
58  
59  
60



18.8% for neurocognition, 12.7% for clinical symptoms and disturbed sleep, and 17.7% were missing for alcohol and substance use. Each analysis had >80% of cases with complete data. Additional analyses revealed that data were not missing at random, and missing data were more likely to occur in younger participants [Welch's  $F(1,102.54) = 4.85, p < 0.05$ ] and in those with an anxiety disorder [ $\chi^2(4) = 26.09, P, 0.001$ ], albeit the effect sizes were small (Cohen's  $d = 0.26$  and Cramer's  $V = 0.16$ , respectively).

Normality was assessed through inspection of Q-Q plots, given inferential measures of non-normality (e.g., Shapiro-Wilk statistic) are overly sensitive in large datasets and almost always return a significant finding<sup>37</sup>. All endogenous variables (e.g., SOFAS) met normality assumptions on visual inspection. Based on visual inspection of the frequency histograms and assessment of the Q-Q plot, the predictor/exogenous variables that departed from normality were positive symptoms, negative symptoms, mania, disorientation, TMT-A, and TMT-B, which were all observed to have a slight positive skew (no others were skewed). Prior studies have found that MLE methods are robust in cases where variables depart from normality where  $N > 600$ , as in the present case<sup>38</sup>. However, other approaches to non-normal data, such as asymptotically distribution free SEM, require no missing data and would unsatisfactorily affect the generalisability of findings as well as statistical power in the current analyses. As such, we utilised the MLE approach.

We first used SEM to evaluate the best-fitting *measurement model* for the following predictors: 1/ neurocognition; 2/ clinical symptoms and disturbed sleep; and 3/ alcohol and substance use. Then, we used SEM to test the *structural model* (i.e., the relationship between predictors and social and occupational functioning) at both the single-predictor and the overall levels in order to explore potential predictors and delineate unique contributions. This was done in a two-step process – first, by testing individual predictors and then by testing the combined predictors - to quantify the amount of overlapping and unique explanatory power. All analyses used a model-trimming approach through an iterative process in which non-significant paths with the smallest contribution were sequentially eliminated from

1 a saturated model (where all variables were allowed to freely co-vary), until a best fitting model was  
2 derived to best explain the relationships between predictors and functional impairment. Finally,  
3  
4 modification indices generated by AMOS were used to optimise model fit (i.e., to inform which paths  
5  
6 and parameters should be added or removed to increase model adequacy), although these were only used  
7  
8 when deemed theoretically meaningful. Residuals were allowed to correlate if theoretically justified (e.g.,  
9  
10 common measurement variance between neuropsychological subtests).  
11  
12  
13  
14  
15

16 Model fit was determined using: (1) the absolute fit  $\chi^2$  statistic; and (2) the relative fit indices:  
17 Bentler comparative fit index (CFI<sup>39</sup>), Bentler-Bonnett non-normed fit index (NFI<sup>40</sup>) and Root Mean  
18 Square Error of Approximation (RMSEA<sup>41</sup>) with 90% confidence interval. An excellent-fitting model is  
19 typically indicated by a non-significant  $\chi^2$  test (indicating a non-significant difference between the  
20 covariance matrix of the data and the model), a CFI and NFI of greater than .90 (indicating that the  
21 current model was superior to a null model where all paths are constrained to zero), and a RMSEA of  
22 less than .05 with an upper confidence interval bound of less than .08 (indicating that the error of  
23 approximation of the model compared with the data was acceptable). In small samples (i.e., less than  
24 200), the  $\chi^2$  statistic has been shown to be an adequate index of absolute model fit.<sup>36</sup> However, as sample  
25 size increases, the  $\chi^2$  statistic (relative to a constant degrees of freedom; df) disproportionately increases,  
26 and is nearly always significant and inappropriately rejects the model irrespective of specified  
27 parameters.<sup>42 43</sup> An alternative solution is to compute a relative,  $\chi^2$ /df ratio, with a value between 2 and  
28 5 considered excellent to adequate fit,<sup>42 44-46</sup> although primary emphasis will be placed on the relative fit  
29 indices as is the established convention.<sup>13</sup>  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 Moderator analyses were conducted allowing a model to be tested in separate sub-groups,  
50 comparing the parameter estimates to determine how predictors of social and occupational functioning  
51 in the final model are moderated by demographic and clinical factors (these were dichotomous to  
52 maintain statistical power within sub-groups for this categorical procedure). For instance, the median-  
53  
54  
55  
56  
57  
58  
59  
60

split on age was performed to determine whether the model held for both younger and older individuals whilst maintaining statistical power. We sought to specifically test whether predictors in affective-spectrum disorders (anxiety, depressive and bipolar disorders) were similarly associated with functional impairment compared with psychotic, developmental or behavioral conditions. We chose to include primary affective disorders (i.e. major depression, bipolar disorder or an anxiety disorder) as a moderator since these disorders have been shown to have carry less neurocognitive burden in recent-onset mood disorders<sup>47 48</sup> and, as such, could potentially influence the role of neurocognition and the magnitude of effects in the statistical models.

## RESULTS

### Sample Characteristics

In total, 1003 patients were recruited. As shown in Table 1 and 2, cross-sectional diagnoses comprised of depressive (n = 449), bipolar (n = 178), psychotic (n = 193), anxiety (n = 109), and developmental or behavioral disorders (n = 74). The mean age was 20.4 years (SD = 4.7), with 54.0% being female (n = 542). Mean educational attainment was 11.7 years (SD = 2.5), with an average predicted IQ of 101.9 (SD = 10.8). The mean SOFAS score was 61.2 (SD = 11.4), indicating moderate levels of impairment. Of the participants with medication data available (87.4%, n = 877), 64.8% were prescribed psychotropic medications (n = 568). Of these 568 cases, 40.6% were prescribed an antidepressant (n = 356), 14.8% were prescribed lithium or an anticonvulsant (n = 130), 33.1% were prescribed any antipsychotic (n = 290), and 4.8% were prescribed a stimulant (n = 42).

[Insert Table 1 about here]

### Single-Predictor Models

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51
- A. Neurocognition.** Inspecting the scree plot, exploratory factor analyses identified two potential latent structures. The one-factor model was a very good fit for the data ( $\chi^2 = 57.3$ ,  $df = 17$ ,  $p < 0.001$ , CFI = 0.980, NFI = 0.972, RMSEA = 0.055, 90% CI = 0.040–0.071), and was a better fit than a two-factor model, whereby Trails A, Trails B and IQ loaded on one latent factor, and IQ, Rey Total, Rey Delay, FAS and Animals loaded on a second latent factor ( $\chi^2 = 76.499$ ,  $df = 11$ ,  $p < 0.001$ , CFI = 0.967, NFI = 0.962, RMSEA = 0.077, 90% CI = 0.061–0.094). Factor loadings on the one-factor model were all significant and ranged from 0.51 to 0.69 (see Figure 1A and legend). Neurocognition was a significant contributor to functional level ( $\beta = 0.39$ ,  $p < 0.001$ ), explaining 15% of the variance.
- B. Core clinical symptom dimensions.** Only three clinical dimensions [depression and anxiety ( $\beta = -0.18$ ,  $p < 0.001$ ), positive symptoms ( $\beta = -0.17$ ,  $p < 0.001$ ), and negative symptoms ( $\beta = -0.26$ ,  $p < 0.001$ )] were associated with functioning, whereas mania and disorientation were not significantly associated ( $p$ 's  $> 0.05$ ). The model demonstrated excellent fit ( $\chi^2 = 8.6$ ,  $df = 8$ ,  $p < 0.379$ , CFI = 0.999, NFI = 0.986, RMSEA = 0.009, 90% CI = 0.000–0.043), with the three dimensions explaining a total of 18% of the variance in functioning (see Figure 1B).
- C. Alcohol and substance use.** Exploratory factor analyses determined that alcohol use did not load with the other substance use variables. Only a two-factor latent model was possible given the number of observed variables and statistical constraints. The two-factor model emerged as an excellent fit for the data ( $\chi^2 = 7.4$ ,  $df = 4$ ,  $p < 0.116$ , CFI = 0.995, NFI = 0.990, RMSEA = 0.033, 90% CI = 0.000–0.069), whereby tobacco, cannabis and other illicit substance use loaded on a single 'substance use' latent variable as distinct from alcohol use (Figure 1C and legend). Only substance use was predictive of functioning ( $\beta = -0.10$ ,  $p < 0.05$ ), explaining 1% of the variance.

52 [Insert Figure 1 about here]

53  
54  
55  
56

## 57 Final Model

58  
59  
60

1  
2 In the overall model, all the factors identified in the single predictor models remained significant, except  
3  
4 for substance use (Figure 2). Neurocognition showed the strongest unique contribution to social and  
5  
6 occupational functioning ( $\beta = 0.36$ ,  $p < 0.001$ ); depressive symptoms were next ( $\beta = -0.24$ ,  $p < 0.001$ ),  
7  
8 followed by negative symptoms ( $\beta = -0.15$ ,  $p < 0.001$ ) and finally positive symptoms ( $\beta = -0.10$ ,  $p <$   
9  
10  $0.001$ ). Together, these four clinical features independently accounted for 31% of the variance in  
11  
12 functioning, with the final model being a very good fit for the data ( $\chi^2 = 279.8$ ,  $df = 119$ ,  $p < 0.000$ , CFI  
13  
14 = 0.956, NFI = 0.926, RMSEA = 0.037, 90% CI = 0.031–0.042). Mania, disorientation, and alcohol and  
15  
16 substance use, all significantly correlated with these four significant features ( $p$ 's  $< 0.05$ ).  
17

18  
19  
20  
21 [Insert Figure 2 about here]  
22  
23  
24  
25

## 26 Moderator Analyses

- 27  
28  
29 • *Age*. As shown in Table 3, positive symptoms were no longer a significant contributor to functioning  
30  
31 in the 12- to 20-year-old group ( $\beta = -0.06$ ,  $p = 0.178$ ). The model with older individuals explained  
32  
33 18% more variance in functional impairment than the model with younger individuals. This was  
34  
35 driven in large part by a difference in predictive strength of neurocognition, whereby it was more  
36  
37 predictive in older ( $\beta = 0.44$ ,  $p < 0.001$ ) than younger individuals ( $\beta = 0.27$ ,  $p < 0.001$ ).  
38  
39
- 40  
41 • *Gender*. Positive symptoms were non-significant in the male sub-group ( $\beta = -0.07$ ,  $p = 0.145$ ),  
42  
43 whereas all other clinical features remained significant ( $p$ 's  $< 0.001$ ). In females, negative symptoms  
44  
45 became non-significant ( $\beta = -0.07$ ,  $p = 0.105$ ), whilst the other contributors remained significant.  
46  
47  
48 The final model was comparable across genders in terms of the total variance explained.  
49

50  
51 [Insert Table 2 about here]  
52  
53

- 54 • *Primary affective disorder diagnosis*. Neurocognition, depression and anxiety, and negative  
55  
56 symptoms remained significant contributors to functional level irrespective of affective disorder  
57  
58

1  
2 diagnosis (see Table 4). By contrast, positive symptoms no longer remained significant in both the  
3  
4 affective disorder ( $\beta = -0.63$ ,  $p = 0.097$ ) and psychosis, developmental or behavioral disorders ( $\beta =$   
5  
6  $-0.102$ ,  $p = 0.123$ ) sub-groups. An additional 14% of the variance in functioning was explained in  
7  
8 individuals with a psychotic, developmental or behavioral disorder, primarily owing to the greater  
9  
10 predictive strength of neurocognition (0.30 vs. 0.43,  $p$ 's  $< 0.001$ ).

- 11  
12  
13  
14 • *Medication usage.* All factors associated with functional impairment remained significant in  
15  
16 participants who were unmedicated. By contrast, positive symptoms no longer remained significant  
17  
18 in medicated individuals ( $\beta = -0.06$ ,  $p = 0.117$ ).

19  
20  
21 [Insert Table 3 about here]  
22  
23  
24  
25  
26

## 27 **Sensitivity Analysis**

28  
29 Restricting the full sample to individuals aged 15-25 years of age ( $N = 794$ ) yielded a very good fitting  
30  
31 model as well ( $\chi^2 = 240.1$ ,  $df = 119$ ,  $p < 0.000$ ,  $CFI = 0.959$ ,  $NFI = 0.924$ ,  $RMSEA = 0.036$ ,  $90\% CI =$   
32  
33  $0.029-0.042$ ). The explained variance remained the same (31% explained). Importantly, all predictors  
34  
35 remained significant with the same effect sizes, with the exception of depression and anxiety, which  
36  
37 became slightly more predictive ( $-0.25 \rightarrow -0.26$ ), and neurocognition, which became slightly less  
38  
39 predictive ( $0.36 \rightarrow 0.35$ ).  
40  
41  
42  
43  
44  
45  
46

## 47 **DISCUSSION**

48  
49 In a large, clinical, transdiagnostic cohort of youth with mental disorders, impaired neurocognition was  
50  
51 the clinical feature most significantly associated with functional impairment. The role of neurocognition  
52  
53 was attenuated in those with an affective disorder diagnosis and in the younger age group. The findings  
54  
55 are relevant as they demonstrate that whilst neurocognitive impairment may undermine functioning in  
56  
57  
58  
59

1 those with psychotic disorders, or in chronic or recurrent mental disorders, they are not specific to such  
2 cases. That is, neurocognitive dysfunction has traditionally been argued as a core, underlying feature of  
3 social and occupational impairments in chronic schizophrenia. However, our current findings support the  
4 burgeoning position that the role of neurocognitive deficits cut across diagnosis and clinical stage.  
5 Nevertheless, it appears that neurocognitive disturbances are more pronounced in those with psychotic,  
6 developmental, or behavioural disorders, converging with evidence of more pronounced cognitive  
7 deficits in children who will go on to develop psychosis compared with those who develop depression  
8 or bipolar disorder<sup>49-51</sup>. Mechanistically, whether neurocognitive dysfunction drives functional  
9 impairment as a few past studies have found<sup>7 28</sup>, and is a consequence of poor functioning remains to be  
10 clarified.

11 Depressive, anxiety and negative symptom dimensions also contributed significantly to level of  
12 social and occupational functioning, supporting previous disorder-specific research.<sup>11 13 28</sup> Importantly,  
13 the contributions of these factors to level of functioning were largely independent of one another, and do  
14 not appear to be moderated by other clinical or demographic factors. By comparison, the role of positive  
15 symptoms diminished considerably in the final model. This finding differs from other research in  
16 psychotic and bipolar disorders, and may reflect the lower prevalence of positive symptoms in our cohort  
17 in contrast to previous studies.<sup>11 13 28</sup> However, it was notable that positive symptoms in older,  
18 unmedicated females remained significantly associated with functioning. As with neurocognition  
19 however, the directionality of findings remains unclear, with some evidence suggesting that it may be  
20 bidirectional in the case of negative symptoms<sup>7 28 52</sup>.

21 Intriguingly, neither alcohol and substance use, nor sleep disturbances, were directly associated  
22 with functional impairment, although these factors remained significantly associated with neurocognition  
23 and clinical symptoms. Therefore, their role in social and occupational functioning does not appear to be  
24 direct, but may operate indirectly (e.g., substance use may impair cognition, which in turn may impair  
25

1  
2 functioning). The indirect effects of alcohol and substance use, as well as sleep and circadian disruptions,  
3  
4 warrant more detailed examination and causal analysis in longitudinal datasets. Moreover, the lack of a  
5  
6 direct association between alcohol and substance use and functioning may be related to the domains of  
7  
8 neurocognitive functions currently tested. That is, the impact of substance use on functioning may be  
9  
10 greatest in other neurocognitive functions that are more directly linked to driving and maintaining alcohol  
11  
12 and substance use behaviours, such as those subserved by the fear, reward and self-control circuitries not  
13  
14 covered in the current neuropsychological battery (e.g., reward-related cue learning, habit formation,  
15  
16 response inhibition).  
17  
18

19  
20  
21 The current findings have important implications for the transdiagnostic, dimensional approach  
22  
23 to psychiatry. Research examining the underlying mechanisms of functional impairment in single- or  
24  
25 dual-diagnosis cohorts have been unable to capture the unique contributions of a comprehensive range  
26  
27 of neurocognitive, symptom, sleep and circadian factors, as well as other psychoactive exposures (i.e.,  
28  
29 substance use, prescribed medications).<sup>22</sup> In particular, neuropsychological studies in psychosis have not  
30  
31 routinely and concurrently assessed depression and anxiety symptoms, hypomania and full-threshold  
32  
33 mania, substance misuse, and sleep disturbance. That is not to say that categorical, nosological  
34  
35 approaches have had little to contribute to the field. Indeed, the key argument underpinning a DSM-  
36  
37 approach is to allow for comparability across studies and so diagnostic determinations are often  
38  
39 necessary. However, in youth, diagnoses tend to be unstable<sup>1</sup> and, as such, not as useful. One plausible  
40  
41 way forward for dimensional psychiatry is to ensure that the samples used in transdiagnostic studies are  
42  
43 characterised as clearly and as comprehensively as possible,<sup>16 53 54</sup> as was attempted in the present  
44  
45 investigation.  
46  
47  
48  
49  
50

51 In terms of limitations, the current analyses were cross-sectional, and future research  
52  
53 investigating moderator and mediator analyses would benefit from cross-lagged, longitudinal path  
54  
55 modelling to disentangle causality.<sup>55</sup> Secondly, the measures used to index clinical symptoms, sleep  
56  
57  
58  
59



1  
2 disturbance, and alcohol and substance use were not as comprehensive as is typical in the sleep and  
3  
4 addiction literatures, and some were not originally designed for use in certain clinical disorders, which  
5  
6 may have reduced sensitivity to detect symptoms (e.g., mania). More detailed examination of these  
7  
8 dimensions in the future will help more definitively determine whether the impact of neurocognition on  
9  
10 functioning is as large as currently identified. Future studies would also benefit from using real-time,  
11  
12 ecological momentary assessment technologies (e.g., substance use monitoring using smartphones,  
13  
14 actigraphy monitoring of physical activity and sleep quality). Thirdly, medication data were not available  
15  
16 for the full sample (12.6% were missing) and, as such, the moderating role of medication status requires  
17  
18 further corroboration (as with the role of medication type). Fourthly, clinical diagnoses assigned to cases  
19  
20 in the current study were by treating psychiatrists and future studies should consider more structured  
21  
22 approaches (e.g., Structured Clinical Interview for DSM), including consideration of the influence of  
23  
24 other comorbid diagnoses (e.g., personality disorders). Further, the age range included in the current  
25  
26 study meant that individuals on the opposite ends of the age spectrum were at different stages of their  
27  
28 cognitive and emotional development (e.g., executive functioning, emotional regulation), although our  
29  
30 sensitivity analyses supports the argument that our findings hold irrespective of age. Further, a  
31  
32 phenotype-approach, as attempted in the current study, would necessarily require converging genetic and  
33  
34 neuroimaging evidence to ensure that the neurocognitive and symptom dimensions identified as  
35  
36 predictive of functioning are linked to specific neural circuitries (e.g., cortico-basal ganglia systems<sup>56</sup>)  
37  
38 and genotype, which would ultimately facilitate the development of next-generation and neuroscience-  
39  
40 informed pharmacotherapies. Finally, it remains to be seen whether the current findings hold in future  
41  
42 studies with less missing data, as well as in studies using measures or approaches that can circumvent  
43  
44 potential biases stemming from non-normally distributed data.  
45  
46  
47  
48  
49  
50  
51  
52

53 This was the first study to examine a broad range of illness-related factors and associations with  
54  
55 functional impairment in a well-powered and broadly transdiagnostic, clinical cohort of more than one  
56  
57  
58  
59  
60

1  
2 thousand young people with mental illness. A significant contribution of the present findings to the  
3  
4 established literature was evidence showing that neurocognition is a strong and reliable, unique predictor  
5  
6 of social and occupational functioning irrespective of diagnosis – in a cohort predominantly comprised  
7  
8 of affective disorders, which has not been previously demonstrated before at this scale. As such, the  
9  
10 functional importance of neurocognitive functions clearly extends beyond the psychosis and  
11  
12 developmental disorders spectrum and appears to become more pronounced with increasing age. Future  
13  
14 studies should attempt to replicate these findings, as well as to clarify the directions of cause and effect.  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## **AUTHORSHIP**

RSCL, DFH, SLN, AJG, NG, JS, EMS and IBH contributed to the conception of the study; RSCL, DFH, MK undertook the data collection, processing and analysis; RSCL wrote the first draft of the manuscript. All authors contributed to data interpretation, discussion and have approved the final manuscript.

## **FUNDING**

This study was supported by grants from the National Health & Medical Research Council (NHMRC) including: Centre of Research Excellence (No. 1061043), NHMRC Fellowship (No. 1046899) and Clinical Research Fellowship (No. 402864). The funders had no input to the study design, data collection, or interpretation, writing of report, or submission for publication.

## **COMPETING INTERESTS**

(1) No authors have support from any company for the submitted work; (2) no authors have relationships with any company that might have an interest in the submitted work; (3) no author, their spouses, partners, or children have financial relationships that may be relevant to the submitted work and; (4) no authors have any non-financial interests that may be relevant to the submitted work.

## **ETHICAL APPROVAL**

This study was approved by the University of Sydney Human Research Ethics Committee (reference 12130; protocol no. 2012/1631).

## **AVAILABILITY OF DATA AND MATERIALS**

The datasets generated and/or analysed during the current study are not publicly available due to the breadth and sensitivity of data collected, which may have implications for individual privacy, but are available from the corresponding author on reasonable request.

**REFERENCES**

1. Bromet EJ, Kotov R, Fochtmann LJ, et al. Diagnostic shifts during the decade following first admission for psychosis. *American Journal of Psychiatry* 2011;168(11):1186-94. doi: 10.1176/appi.ajp.2011.11010048 [published Online First: 2011/06/17]
2. Hickie IB, Scott J, Hermens DF, et al. Clinical classification in mental health at the cross-roads: which direction next? *BMC medicine* 2013;11:125. doi: 10.1186/1741-7015-11-125 [published Online First: 2013/05/16]
3. McGorry PD, Hickie IB, Yung AR, et al. Clinical staging of psychiatric disorders: A heuristic framework for choosing earlier, safer and more effective interventions. *Australian and New Zealand Journal of Psychiatry* 2006;40(8):616-22.
4. Cross SPM, Hermens DF, Scott EM, et al. A Clinical Staging Model for Early Intervention Youth Mental Health Services. *Psychiatric Services* 2014;65(7):939-43. doi: 10.1176/appi.ps.201300221
5. Lee RSC, Redoblado MA, Naismith SL, et al. Cognitive remediation improves memory and psychosocial functioning in first-episode psychiatric out-patients. *Psychological Medicine* 2013;43(6):1161-73.
6. Cross SPM, Scott J, Hickie IB. Predicting early transition from sub-syndromal presentations to major mental disorders. *BJPsych Open* 2017;3(5):223-27. doi: 10.1192/bjpo.bp.117.004721
7. Lee RSC, Hermens D, Scott J, et al. A Transdiagnostic Study of Education, Employment, and Training Outcomes in Young People with Mental Illness. *Psychological Medicine* 2017;47:2061–70.
8. O'Dea B, Lee RS, McGorry PD, et al. A prospective cohort study of depression course, functional disability, and NEET status in help-seeking young adults. *Soc Psychiatry Psychiatr Epidemiol* 2016 doi: 10.1007/s00127-016-1272-x [published Online First: 2016/08/09]
9. Davidson L, O'Connell MJ, Tondora J, et al. Recovery in Serious Mental Illness: A New Wine or Just a New Bottle? *Professional Psychology: Research and Practice* 2005;36(5):480-87. doi: 10.1037/0735-7028.36.5.480
10. World Health Organization. Mental Health Action Plan 2013-2020. Geneva, Switzerland: World Health Organization 2013.
11. Bowie CR, Depp C, McGrath JA, et al. Prediction of real-world functional disability in chronic mental disorders: A comparison of schizophrenia and bipolar disorder. *The American Journal of Psychiatry* 2010;167(9):1116-24.

12. Lee RSC, Hermens DF, Redoblado MA, et al. Neuropsychological and socio-occupational functioning in young psychiatric outpatients: a longitudinal investigation. *PLOS ONE* 2013;8(3):e58176. doi: 10.1371/journal.pone.0058176
13. Galderisi S, Rossi A, Rocca P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2014;13(3):275-87. doi: 10.1002/wps.20167
14. Thomas ML, Green MF, Helleman G, et al. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. *JAMA psychiatry (Chicago, Ill)* 2017;74(1):37-46. doi: 10.1001/jamapsychiatry.2016.2980 [published Online First: 2016/12/08]
15. Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. *The Lancet* 2013 doi: [http://dx.doi.org/10.1016/S0140-6736\(13\)61611-6](http://dx.doi.org/10.1016/S0140-6736(13)61611-6)
16. Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. *World psychiatry : official journal of the World Psychiatric Association (WPA)* 2014;13(1):28-35. doi: 10.1002/wps.20087
17. Robbins TW, Gillan CM, Smith DG, et al. Neurocognitive endophenotypes of impulsivity and compulsivity: towards dimensional psychiatry. *Trends in Cognitive Sciences* 2012;16(1):81-91. doi: 10.1016/j.tics.2011.11.009
18. Millan MJ, Agid Y, Brüne M, et al. Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. *Nature Reviews Drug Discovery* 2012;11(2):141-68.
19. Hägele C, Schlagenhaut F, Rapp M, et al. Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders. *Psychopharmacology* 2015;232(2):331-41. doi: 10.1007/s00213-014-3662-7
20. Yee CM, Javitt DC, Miller GA. Replacing DSM Categorical Analyses With Dimensional Analyses in Psychiatry Research: The Research Domain Criteria Initiative. *JAMA psychiatry (Chicago, Ill)* 2015;72(12):1159-60. doi: 10.1001/jamapsychiatry.2015.1900 [published Online First: 2015/11/13]
21. Miller GA. Mistreating Psychology in the Decades of the Brain. *Perspectives on psychological science : a journal of the Association for Psychological Science* 2010;5(6):716-43. doi: 10.1177/1745691610388774 [published Online First: 2011/09/29]

22. Iorfino F, Hickie IB, Lee RSC, et al. The underlying neurobiology of key functional domains in young people with mood and anxiety disorders: a systematic review. *BMC Psychiatry* 2016;16(1):1-38. doi: 10.1186/s12888-016-0852-3
23. Lee RSC, Hermens DF, Naismith SL, et al. Neuropsychological and functional outcomes in recent-onset major depression, bipolar disorder and schizophrenia-spectrum disorders: A longitudinal cohort study. *Translational Psychiatry* 2015;5:e555.
24. Hermens D, Naismith S, Lagopoulos J, et al. Neuropsychological profile according to the clinical stage of young persons presenting for mental health care. *BMC Psychology* 2013;1(1):8.
25. Scott EM, Hermens DF, Glozier N, et al. Targeted primary care-based mental health services for young Australians. *Medical Journal of Australia* 2012;196:136-40.
26. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. *American Journal of Psychiatry* 1992;149(9):1148-56.
27. Lee RSC, Hermens DF, Redoblado-Hodge MA, et al. Neuropsychological and socio-occupational functioning in young psychiatric outpatients: a longitudinal investigation. *PLoS One* 2013;8 doi: 10.1371/journal.pone.0058176
28. Green MF, Helleman G, Horan WP, et al. From perception to functional outcome in schizophrenia: modeling the role of ability and motivation. *Archives of General Psychiatry* 2012;69(12):1216-24. doi: 10.1001/archgenpsychiatry.2012.652 [published Online First: 2012/10/03]
29. Strauss E, Sherman EMS, Spreen O. A Compendium of neuropsychological tests: Administration, norms, and commentary. 3rd ed. New York: Oxford University Press 2006.
30. Lezak MD, Howieson DB, Bigler ED, et al. Neuropsychological Assessment. 5th ed. ed. New York: Oxford University Press 2012.
31. Dazzi F, Shafer A, Lauriola M. Meta-analysis of the Brief Psychiatric Rating Scale - Expanded (BPRS-E) structure and arguments for a new version. *Journal of Psychiatric Research* 2016;81:140-51. doi: 10.1016/j.jpsychires.2016.07.001
32. Londborg PD, Smith WT, Glaudin V, et al. Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression. *Journal of Affective Disorders* 2000;61(1-2):73-79. doi: [https://doi.org/10.1016/S0165-0327\(99\)00195-0](https://doi.org/10.1016/S0165-0327(99)00195-0)
33. Hamilton M. A rating scale for depression. *Journal of Neurology, Neurosurgery & Psychiatry* 1960;23(1):56-62.
34. Saunders JB, Aasland OG, Babor TF, et al. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with

- 1 Harmful Alcohol Consumption--II. *Addiction (Abingdon, England)* 1993;88(6):791-804.  
2  
3 [published Online First: 1993/06/01]  
4  
5 35. WHO ASSIST Working Group. The Alcohol, Smoking and Substance Involvement Screening Test  
6 (ASSIST): Development, reliability and feasibility. *Addiction (Abingdon, England)*  
7 2002;97(9):1183-94. [published Online First: 2002/08/30]  
8  
9 36. Arbuckle JL. IBM SPSS Amos 20 User's Guide: IBM Corporation 2011.  
10  
11 37. Miot HA. Avaliação da normalidade dos dados em estudos clínicos e experimentais. *Jornal*  
12 *Vascular Brasileiro* 2017;16:88-91.  
13  
14 38. Muthén B, Kaplan D. A comparison of some methodologies for the factor analysis of non-normal  
15 Likert variables. *British Journal of Mathematical and Statistical Psychology* 1985;38(2):171-89.  
16 doi: doi:10.1111/j.2044-8317.1985.tb00832.x  
17  
18 39. Bentler PM. Comparative Fit Indexes in Structural Models. *Psychological Bulletin*  
19 1990;107(2):238-46.  
20  
21 40. Bentler PM, Bonett DG. Significance tests and goodness of fit in the analysis of covariance  
22 structures. *Psychological Bulletin* 1980;88(3):588-606.  
23  
24 41. Steiger JH. Tests for comparing elements of a correlation matrix. *Psychological Bulletin*  
25 1980;87(2):245-51.  
26  
27 42. Schermelleh-Engel K, Moosbrugger H, Müller H. Evaluating the fit of structural equation models:  
28 Tests of significance and descriptive goodness-of-fit measures. *Methods of Psychological*  
29 *Research-Online* 2003;8:23-74. doi: citeulike-article-id:7222182  
30  
31 43. Jöreskog K, Sörbom D. LISREL 8: Structural Equation Modeling with the SIMPLIS Command  
32 Language Chicago, IL: Scientific Software International Inc. 1993.  
33  
34 44. Wheaton B, Muthen B, Alwin D, et al. Assessing Reliability and Stability in Panel Models.  
35 *Sociological Methodology* 1977;8:84-136.  
36  
37 45. Tabachnick B, Fidell L. Using Multivariate Statistics (5th ed.). New York: Allyn and Bacon 2007.  
38  
39 46. Kline R. Principles and Practice of Structural Equation Modeling (2nd ed.) New York: The  
40 Guilford Press 2005.  
41  
42 47. Lee RSC, Hermens DF, Porter MA, et al. A meta-analysis of cognitive deficits in first-episode  
43 Major Depressive Disorder. *Journal of Affective Disorders* 2012;140(2):113-24. doi:  
44 10.1016/j.jad.2011.10.023  
45  
46 48. Lee RSC, Hermens DF, Scott J, et al. A meta-analysis of neuropsychological functioning in first-  
47 episode bipolar disorders. *Journal of Psychiatric Research* 2014;57:1-11. doi:  
48 10.1016/j.jpsychires.2014.06.019  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59

- 1  
2 49. Reichenberg A, Weiser M, Rabinowitz J, et al. A population-based cohort study of premorbid  
3 intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective  
4 disorder, and nonpsychotic bipolar disorder. *Am J Psychiatry* 2002;159(12):2027-35. [published  
5 Online First: 2002/11/27]  
6  
7  
8  
9 50. Koenen KC, Moffitt TE, Roberts AL, et al. Childhood IQ and adult mental disorders: a test of the  
10 cognitive reserve hypothesis. *Am J Psychiatry* 2009;166(1):50-7. doi:  
11 10.1176/appi.ajp.2008.08030343 [published Online First: 2008/12/03]  
12  
13  
14 51. Zammit S, Allebeck P, David AS, et al. A longitudinal study of premorbid IQ score and risk of  
15 developing schizophrenia, bipolar disorder, severe depression, and other nonaffective psychoses.  
16 *Archives of General Psychiatry* 2004;61(4):354-60. doi: 10.1001/archpsyc.61.4.354  
17  
18  
19 52. Nakagami E, Hoe M, Brekke JS. The Prospective Relationships Among Intrinsic Motivation,  
20 Neurocognition, and Psychosocial Functioning in Schizophrenia. *Schizophrenia Bulletin*  
21 2010;36(5):935-48. doi: 10.1093/schbul/sbq043  
22  
23  
24 53. Casey BJ, Craddock N, Cuthbert BN, et al. DSM-5 and RDoC: progress in psychiatry research?  
25 *Nature reviews Neuroscience* 2013;14(11):810-14. doi: 10.1038/nrn3621  
26  
27  
28 54. Craddock N, Owen MJ. Rethinking psychosis: the disadvantages of a dichotomous classification  
29 now outweigh the advantages. *World psychiatry : official journal of the World Psychiatric*  
30 *Association (WPA)* 2007;6(2):84-91. [published Online First: 2008/02/01]  
31  
32  
33 55. Breitborde NJ, Srihari VH, Pollard JM, et al. Mediators and moderators in early intervention  
34 research. *Early Interv Psychiatry* 2010;4(2):143-52. doi: 10.1111/j.1751-7893.2010.00177.x  
35  
36 [published Online First: 2010/06/12]  
37  
38 56. Griffiths KR, Lagopoulos J, Hermens DF, et al. Impaired causal awareness and associated cortical–  
39 basal ganglia structural changes in youth psychiatric disorders. *NeuroImage: Clinical* 2016;12:285-  
40 92. doi: <http://dx.doi.org/10.1016/j.nicl.2016.06.017>  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Table 1** Demographic, clinical and functional characteristics across diagnostic sub-groups

	DEPRESSION <sup>1</sup> (n = 449)		BIPOLAR <sup>2</sup> (n = 178)		PSYCHOSIS <sup>3</sup> (n = 193)		ANXIETY <sup>4</sup> (n = 109)		DEV/BEHAV <sup>5</sup> (n = 74)	
	M	SD	M	SD	M	SD	M	SD	M	SD
Age	19.8	4.3	21.6	4.8	22.2	4.6	19.9	4.8	17.0	4.6
Education (years)	11.6	2.4	12.3	2.2	12.0	2.4	11.5	2.7	10.0	2.8
BPRS Depression (/7)	2.4	0.8	2.2	0.8	2.1	0.9	2.3	0.9	1.7	0.7
BPRS Mania (/7)	1.3	0.5	1.5	0.6	1.4	0.4	1.4	0.4	1.5	0.7
BPRS Positive (/7)	1.3	0.4	1.4	0.5	1.8	0.7	1.4	0.5	1.3	0.4
BPRS Negative (/7)	1.5	0.6	1.3	0.5	1.9	0.8	1.5	0.7	1.5	0.6
BRPS Disorientation (/7)	1.2	0.5	1.1	0.5	1.2	0.6	1.2	0.5	1.2	0.5
HDRS Sleep (/6)	2.0	1.8	1.7	1.7	1.3	1.6	1.5	1.5	1.8	1.7
AUDIT Alcohol Use (/40)	6.8	7.4	9.0	8.4	6.2	8.0	4.4	6.4	5.1	7.5
WHO-ASSIST Tobacco Use (/4)	1.3	1.6	1.6	1.7	1.7	1.9	1.0	1.5	1.4	1.7
WHO-ASSIST Cannabis Use (/4)	0.7	1.2	0.7	1.3	0.4	1.0	0.4	0.9	0.7	1.3
WHO-ASSIST Other Illicit Substance Use (/4)	0.1	0.3	0.1	0.3	0.1	0.2	0.1	0.3	0.1	0.3
SOFAS	61.8	10.7	63.9	11.5	55.9	12.1	63.2	11.1	61.7	9.8
	N	%	N	%	N	%	N	%	N	%
Gender (female)	277	61.7	129	72.5	58	30.1	58	53.2	20	27.0
Medicated <sup>†</sup>	231	60.0	128	77.6	140	77.3	37	45.7	32	49.2
Antidepressants	201	52.2	63	38.2	55	30.4	25	30.9	12	18.5
Lithium/Anticonvulsants	28	7.3	69	41.8	24	13.3	6	7.4	3	4.6
Antipsychotics	71	18.4	77	46.7	125	69.1	9	11.1	8	12.3
Stimulants	14	3.6	7	4.2	3	1.7	4	4.9	14	21.5

AUDIT–Alcohol Use Disorders Identification Test; BPRS–Brief Psychiatric Rating Scale; DEV/BEHAV–Developmental/Behavioral; HDRS–Hamilton Depression Rating Scale; SOFAS–Social and Occupational Functioning Assessment Scale; WHO-ASSIST–World Health Organization – Alcohol, Smoking and Substance Involvement Screening Test

<sup>1</sup> Major Depressive Disorder (n=313), Dysthymic Disorder (n=4), Depressive Disorder Not Otherwise Specified (n=132)

<sup>2</sup> Bipolar I Disorder (n=13), Bipolar II Disorder (n=25), Cyclothymic Disorder (n=1), Bipolar Disorder Not Otherwise Specified (n=139)

<sup>3</sup> Schizophrenia (n=53), Schizophreniform Disorder (n=15), Schizoaffective Disorder (n=26), Brief Psychotic Disorder (n=11), Substance-Induced Psychotic Disorder (n=14), Psychotic Disorder Not Otherwise Specified (n=74)

<sup>4</sup> Panic Disorder (n=4), Social Phobia (n=29), Obsessive-Compulsive Disorder (n=11), Posttraumatic Stress Disorder (n=5), Generalised Anxiety Disorder (n=60)

<sup>5</sup> Asperger's Disorder (n=16), Attention-Deficit/Hyperactivity Disorder (n=47), Conduct Disorder (n=7), Oppositional Defiant Disorder (n=4)

<sup>†</sup> Medication data was available in 877 individuals (87.4%), with missing data for the typologies of Depression (n=64), Bipolar (n=13), Psychosis (n=12), Anxiety (n=28), Developmental (n=9)

**Table 2** Neuropsychological functioning across diagnostic sub-groups

	DEPRESSION (n = 449)		BIPOLAR (n = 178)		PSYCHOSIS (n = 193)		ANXIETY (n = 109)		DEV/BEHAV (n = 74)	
	M	SD	M	SD	M	SD	M	SD	M	SD
IQ <sup>1</sup>	103.25	10.49	102.82	9.08	99.99	10.47	102.66	9.59	95.30	14.83
Trails A <sup>2</sup>	-0.01	1.32	0.16	1.06	-0.31	1.01	0.12	0.96	-0.03	1.07
Trails B <sup>2</sup>	-0.44	1.53	-0.47	1.92	-1.22	2.23	-0.50	1.59	-0.85	2.16
Rey Total <sup>2</sup>	-0.06	1.27	-0.18	1.20	-1.12	1.46	0.09	1.93	-0.48	1.42
Rey Delay <sup>2</sup>	0.03	1.34	-0.27	1.38	-1.07	1.51	0.18	2.29	-0.29	1.22
FAS <sup>2</sup>	-0.31	1.15	-0.04	1.07	-0.56	1.00	-0.37	1.15	-0.86	1.09
Animals <sup>2</sup>	0.23	1.20	0.45	1.25	-0.28	1.08	0.26	1.17	-0.03	0.94

<sup>1</sup> Age-adjusted; normative M = 100; SD = 15.

<sup>2</sup> Demographically-adjusted; normative M= 0.00; SD = 1.00.

**Table 3** Analyses of demographic factors (age, gender) as moderators of the relationships between predictors and functional outcome in the final model

	Age <sup>†</sup>				Gender <sup>‡</sup>			
	12-20 Years (n = 539)		21-36 Years (n = 464)		Male (n = 461)		Female (n = 542)	
	$\beta$	p-value	$\beta$	p-value	$\beta$	p-value	$\beta$	p-value
<b>Neurocognition</b>	.27	.000	.44	.000	.35	.000	.35	.000
<b>Depression and Anxiety</b>	-.28	.000	-.22	.000	-.23	.000	-.30	.000
<b>Positive Symptoms</b>	-.06	.178	-.14	.002	-.07	.145	-.12	.004
<b>Negative Symptoms</b>	-.13	.005	-.18	.000	-.19	.000	-.07	.105

<sup>†</sup> 12-20 Years (Subgroup Model, R<sup>2</sup>=.24); 21-36 Years (Subgroup Model, R<sup>2</sup>=.40)

<sup>‡</sup> Male (Subgroup Model, R<sup>2</sup>=.32); Female (Subgroup Model, R<sup>2</sup>=.29)

**Table 4** Analyses of clinical factors (primary affective disorder, medication usage) moderating the relationship between predictors and functional outcome in the final model

	Primary Affective Disorder <sup>†</sup>				Medication Usage <sup>‡</sup>			
	Yes (n = 736)		No (n = 267)		Nil (n = 309)		Medicated (n = 568)	
	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value	$\beta$	<i>p</i> -value
<b>Neurocognition</b>	.30	.000	.43	.000	.38	.000	.38	.000
<b>Depression and Anxiety</b>	-.29	.000	-.24	.000	-.15	.007	-.24	.000
<b>Positive Symptoms</b>	-.06	.097	-.10	.123	-.22	.000	-.06	.117
<b>Negative Symptoms</b>	-.12	.003	-.16	.009	-.19	.000	-.13	.002

<sup>†</sup> Yes (Subgroup Model,  $R^2=.24$ ); No (Subgroup Model,  $R^2=.38$ )

<sup>‡</sup> Nil (Subgroup Model,  $R^2=.38$ ); Medicated (Subgroup Model,  $R^2=.29$ )

1  
2 **Figure 1** Combined measurement and structural models for functioning and (A) neurocognition, (B) core  
3 clinical symptoms, and (C) alcohol and substance use.  
4

5 *Legend:*

6 All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except path between  
7 substance use and functional outcome; where  $p < .05$ )

8 Factor Loadings for (A) Neurocognition (all  $p$ 's  $< .001$ ): IQ (.58), Trails A (-.51), Trails B (-.55), Rey Total (.69),  
9 Rey Delay (.59), FAS (.57), Animals (.51)

10 Factor Loadings for (C) Substance Use (all  $p$ 's  $< .001$ ): Tobacco (.81), Cannabis (.64), Other (.68)  
11  
12  
13  
14

15 **Figure 2** Final model.

16  
17 *Legend:*

18 All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except correlation  
19 between substance use and positive symptoms, where  $p < .05$ ). Where no path is drawn it denotes no significant  
20 relationship between the variables (see Figure 1 for all factor loadings of latent variables).  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1 Combined measurement and structural models for functioning and (A) neurocognition, (B) core clinical symptoms, and (C) alcohol and substance use.

#### Legend:

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except path between substance use and functional outcome; where  $p < .05$ )

Factor Loadings for (A) Neurocognition (all  $p$ 's  $< .001$ ): IQ (.58), Trails A (-.51), Trails B (-.55), Rey Total (.69), Rey Delay (.59), FAS (.57), Animals (.51)

Factor Loadings for (C) Substance Use (all  $p$ 's  $< .001$ ): Tobacco (.81), Cannabis (.64), Other (.68)

230x199mm (300 x 300 DPI)




Figure 2 Final model.

Legend:

All unidirectional (correlation) and directional (regression) paths are significant at  $p < .001$  (except correlation between substance use and positive symptoms, where  $p < .05$ ). Where no path is drawn it denotes no significant relationship between the variables (see Figure 1 for all factor loadings of latent variables).

393x208mm (300 x 300 DPI)

**STROBE Statement**—checklist of items that should be included in reports of observational studies

RE: “*A cross-sectional study of clinical, neurocognitive, and demographic factors associated with functional impairment in the Brain and Mind Youth Cohort*”

	Item No	Recommendation	Authors Response
<b>Title and abstract</b>	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract <b>Pg. 1</b>	Yes
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found <b>Pg. 2</b>	Yes
<b>Introduction</b>			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported <b>Pg. 4-6</b>	Yes
Objectives	3	State specific objectives, including any prespecified hypotheses <b>Pg. 6</b>	Yes
<b>Methods</b>			
Study design	4	Present key elements of study design early in the paper <b>Pg. 6-7</b>	Yes
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection <b>Pg. 7</b>	Yes
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants <b>Pg. 7</b>	Yes
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	NA
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable <b>Pg. 7-11</b>	Yes
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group <b>Pg. 8</b>	Yes
Bias	9	Describe any efforts to address potential sources of bias <b>Pg. 10-11</b>	Yes
Study size	10	Explain how the study size was arrived at <b>Pg. 10</b>	Yes
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why <b>Pg. 9-11</b>	Yes
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding <b>Pg. 9-11</b>	Yes
		(b) Describe any methods used to examine subgroups and interactions <b>Pg. 10-11</b>	Yes
		(c) Explain how missing data were addressed <b>Pg. 9</b>	Yes
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls	NA



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

was addressed

~~Cross-sectional study~~—If applicable, describe analytical methods taking account of sampling strategy

(e) Describe any sensitivity analyses

NA

Continued on next page

For peer review only

Results			Authors Response
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed <a href="#">Pg. 11</a>	Yes
		(b) Give reasons for non-participation at each stage	NA
		(c) Consider use of a flow diagram	NA
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders <a href="#">Pg. 11</a>	Yes
		(b) Indicate number of participants with missing data for each variable of interest <a href="#">Pg. 9</a>	Yes
		© <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	NA
Outcome data	15*	<del><i>Cohort study</i>—Report numbers of outcome events or summary measures over time</del>	Yes
		<del><i>Case-control study</i>—Report numbers in each exposure category, or summary measures of exposure</del>	
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures <a href="#">Pg. 11</a>	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included <a href="#">Pg. 12-13</a>	Yes
		(b) Report category boundaries when continuous variables were categorized <a href="#">Pg. 10-11</a>	Yes
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	NA
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses <a href="#">Pg. 11-14</a>	Yes
<b>Discussion</b>			
Key results	18	Summarise key results with reference to study objectives <a href="#">Pg. 14-15</a>	Yes
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias <a href="#">Pg. 15-16</a>	Yes
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence <a href="#">Pg. 14-16</a>	Yes
Generalisability	21	Discuss the generalisability (external validity) of the study results <a href="#">Pg. 16</a>	Yes
<b>Other information</b>			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based <a href="#">Pg. 17</a>	Yes

\*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely

1  
2 available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at  
3 <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is  
4 available at [www.strobe-statement.org](http://www.strobe-statement.org).  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60